<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Metastasis Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Metastasis Rev</journal-id><journal-title-group><journal-title>Cancer Metastasis Reviews</journal-title></journal-title-group><issn pub-type="ppub">0167-7659</issn><issn pub-type="epub">1573-7233</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5721123</article-id><article-id pub-id-type="publisher-id">9699</article-id><article-id pub-id-type="doi">10.1007/s10555-017-9699-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>(Immuno)proteasomes as therapeutic target in acute leukemia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Cloos</surname><given-names>Jacqueline</given-names></name><address><phone>31 20 4443838</phone><email>j.cloos@vumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Roeten</surname><given-names>Margot SF</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Franke</surname><given-names>Niels E</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>van Meerloo</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zweegman</surname><given-names>Sonja</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kaspers</surname><given-names>Gertjan JL</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jansen</surname><given-names>Gerrit</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Departments of Pediatric Oncology/Hematology, </institution><institution>VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Departments of Hematology, </institution><institution>VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.487647.e</institution-id><institution>Princess M&#x000e0;xima Center, </institution></institution-wrap>Utrecht, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>Amsterdam Rheumatology and Immunology Center, </institution><institution>VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>36</volume><issue>4</issue><fpage>599</fpage><lpage>615</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and second-generation proteasome inhibitors in leukemia treatment from a preclinical and clinical perspective. Potential markers for proteasome inhibitor sensitivity and/or resistance emerging from leukemia cell line models and clinical sample studies will be discussed focusing on the role of immunoproteasome and constitutive proteasome (subunit) expression, <italic>PSMB5</italic> mutations, and alternative mechanisms of overcoming proteolytic stress.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Leukemia</kwd><kwd>Constitutive proteasome</kwd><kwd>Immunoproteasome</kwd><kwd>Proteasome inhibition</kwd><kwd>Drug resistance</kwd></kwd-group><funding-group><award-group><funding-source><institution>VU University Medical Center (VUmc)</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Hematological malignancies comprise of many subgroups including chronic and acute leukemia, lymphoma, and multiple myeloma (MM). In this review, we focus exclusively on acute leukemia, which can be divided into two major subgroups: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In children, the majority of leukemia cases are ALL [<xref ref-type="bibr" rid="CR1">1</xref>], while AML is more prevalent in adults with leukemia [<xref ref-type="bibr" rid="CR2">2</xref>]. With a 5-year overall survival (OS) of 83&#x02013;94% [<xref ref-type="bibr" rid="CR3">3</xref>], the prognosis of pediatric ALL is considerably better as compared to adults (5-year OS 15&#x02013;35%, depending on age) [<xref ref-type="bibr" rid="CR4">4</xref>]. A similar difference in prognosis between children and adults is seen in AML with a 5-year OS of, respectively, 65&#x02013;70% and 10&#x02013;45% (depending on age) [<xref ref-type="bibr" rid="CR5">5</xref>]. The main reasons for treatment failure in both children and adults are intrinsic or acquired drug resistance in a subset of leukemia cells that are responsible for refractory disease or the development of relapse, which have a dismal prognosis. Since the (emergence of) drug resistance is one of the limiting factors that impacts long-term efficacy of anti-leukemic drugs, the search for new anti-leukemic drugs with novel mechanisms of action is an ongoing challenge.</p><p id="Par3">Most anti-leukemic drugs are targeted against DNA replication to interfere with abundant cell proliferation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). For leukemia cells to expand, they also rely on a very high protein turnover. In normal cells, with normal chromosome numbers and normal protein balance, protein homeostasis is maintained mainly by the ubiquitin-proteasome system (UPS) [<xref ref-type="bibr" rid="CR6">6</xref>]. Besides rapid cell growth, leukemia cells also feature many chromosomal and molecular aberrations, including chromosomal translocations (e.g<italic>.</italic>, t(8:21), Inv(16)), hypo- and hyper-diploidy, activating mutations (e.g<italic>.</italic>, <italic>FLT3/ITD</italic>, <italic>cKIT</italic>), and splicing defects, the latter leading to many different protein isoforms [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Together, this leads to an aberrant protein expression, which imposes an inherent heavy burden on the UPS. These considerations set the stage for therapeutic interventions of UPS-targeting with proteasome inhibitors (PIs) [<xref ref-type="bibr" rid="CR9">9</xref>], of which bortezomib (BTZ) as the first prototypical PI proved successful in therapy-refractory multiple myeloma (MM) [<xref ref-type="bibr" rid="CR10">10</xref>]. Currently, first line treatment of MM includes BTZ and extends to clinical evaluations of next-generation PIs. Updates of PI treatment in MM have been subject of several recent dedicated reviews [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Overview of cytotoxicity mechanism of chemotherapy drugs commonly used in acute leukemia treatment</p></caption><graphic xlink:href="10555_2017_9699_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par4">This review will primarily focus on the application of PIs in acute leukemia, in particular refractory disease. Since many novel drugs with different mechanisms of action are currently available, it is crucial to select those patients for certain PI who will benefit from the treatment. Therefore, it is of clinical relevance to understand the mechanism of action of PIs in leukemia and identify parameters that can help to define (non)-responsiveness to PIs. To this end, this review provides a comprehensive overview on the molecular mechanisms of action and resistance to PIs in leukemia as well as current applications of PIs in clinical trials in leukemia patients.</p></sec><sec id="Sec2"><title>Proteasome inhibitors in leukemia</title><p id="Par5">In the context of hematological cells, it is of importance to recognize that the proteasome composition is highly skewed for &#x0003e;&#x000a0;70% towards immunoproteasomes (iP) over constitutive proteasomes (cP) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The three catalytically active &#x003b2;-subunits (&#x003b2;1, &#x003b2;2, and &#x003b2;5) of the constitutive proteasome and the immunoproteasome counterparts &#x003b2;1i, &#x003b2;2i, and &#x003b2;5i harbor caspase-like, trypsin-like, and chymotrypsin-like proteolytic activity, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Subunit composition and inhibitors targeting of constitutive and immunoproteasomes. <bold>a</bold> 20S core proteasome and <bold>b</bold> fully assembled immunoproteasome with various cap proteins. <bold>c</bold> Clinically active and experimental inhibitors of constitutive- and/or immunoproteasome. <italic>Adapted from Verbrugge</italic> et al. <italic>2015</italic> [<xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><graphic xlink:href="10555_2017_9699_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par6">iP expression is markedly induced upon stimulation by inflammatory cytokines such as IFN&#x003b3; and TNF&#x003b1; [<xref ref-type="bibr" rid="CR16">16</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b). One of the primary functions of iP is to broaden the spectrum of generating antigenic peptides for presentation on MHC class I molecules [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], but also additional functions for iPs have been defined, e.g., clearance of polyubiquitinated protein aggregates emerging under inflammatory oxidative stress conditions [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). Given the abundance of iP in leukemia cells, selective targeting of iP is an attractive treatment option [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par7">BTZ and next-generation PIs [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] have been evaluated in preclinical and clinical studies as potential anti-leukemia drugs. An overview of their properties is provided in Table <xref rid="Tab1" ref-type="table">1</xref>. BTZ is a reversible PI primarily targeting the &#x003b2;5 catalytic active subunit of the proteasome. Next-generation PIs differ from BTZ by being irreversible inhibitors (e.g., carfilzomib (CFZ)), favoring oral administration (e.g., ixazomib (IXA)), attenuating hematological and neurological side effects and overcoming BTZ-associated resistance modalities [<xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, these next-generation PIs display selectivity for cP and iP, and subunits other than &#x003b2;5 [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Initial <italic>ex vivo</italic> activity studies of BTZ and next-generation inhibitors of cP (CFZ, ONX-0912) and iP (ONX-0914) revealed considerable inter-patient variabilities but overall greater potency in ALL than AML cells [<xref ref-type="bibr" rid="CR48">48</xref>]. Moreover, BTZ, CFZ, and ONX-0912 were 3&#x02013;10-fold more potent than the iP inhibitor ONX-914. Interestingly, this study also showed that a higher ratio of immunoproteasome over constitutive proteasome levels in leukemia cells was a good indicator for PI sensitivity. An overview of selected preclinical studies of several PIs in ALL and AML cell lines and primary cells is summarized in Table <xref rid="Tab2" ref-type="table">2</xref>. Overall, these data show the relevance of preclinical studies to unravel the individual specific mechanisms of action of PIs related to apoptosis induction. In addition, these data reveal promising combination strategies for improvement of successful PI therapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Overview of current proteasome inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Class</th><th>Compounds</th><th>Binding to proteasome</th><th>Specificity and mechanisms</th></tr></thead><tbody><tr><td>Peptide aldehydes</td><td>MG-132, ALLnL, ALLnM, LLnV, PSI</td><td>Reversible</td><td>Interact with the catalytic threonine residue of the proteasome.</td></tr><tr><td>Peptide boronates</td><td>Bortezomib, MG-262, PS273<break/>CEP-18770 (delanzomib)<break/>MLN9708/MLN2238 (ixazomib citrate/ixazomib)</td><td>Reversible</td><td>Selective proteasome inhibitors. Interact with the catalytic threonine residue of the proteasome.</td></tr><tr><td>Peptide vinyl sulfones</td><td>NLVS, YLVS</td><td>Irreversible</td><td>Interact with &#x003b2;-subunits of the proteasome.</td></tr><tr><td>Peptide epoxyketones</td><td>Dihydroeponemycin<break/>Epoxomycin<break/>PR-171 (carfilzomib)<break/>PR-047 (ONX 0912, oprozomib)</td><td>Irreversible</td><td>Selective proteasome inhibitors. Bind specifically to &#x003b2;5-subunit of the proteasome.</td></tr><tr><td/><td>PR-957 (ONX 0914)<break/>PR-924</td><td/><td>Selective immune proteasome inhibitors. Bind to immune &#x003b2;-subunits of the proteasome.</td></tr><tr><td>&#x003b2;-Lactones</td><td>Lactacystin</td><td>Irreversible</td><td>Relatively specific but weak proteasome inhibitors. Binds to &#x003b2;-subunits of the proteasome.</td></tr><tr><td/><td>NPI-0052 (marizomib)</td><td>Irreversible</td><td>Binds to &#x003b2;-subunits of the proteasome.</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>MG-132</italic> Carbobenzoxy-L-leucyl-L-leucyl-leucinal, <italic>ALLnL</italic> N-acetyl-L-leucyl-L-leucyl-L-norleucinal, <italic>ALLnM</italic> N-acetyl-L-leucyl-L-leucyl-Lmethioninal, <italic>LLnV</italic> N-Carbobenzoxy-L-leucyl-L-norvalinal, <italic>PSI</italic> N-carbobenzoxy-L-isoleucyl-L-&#x003b3;-t-butyl-L-glutamyl-L-alanyl-L-leucinal, Leu-Leu-vinyl sulfone, <italic>MG-262</italic>N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucyl boronic acid. See for details [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Selection of preclinical studies of proteasome inhibitors in leukemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Proteasome inhibitors</th><th>Leukemic cells</th><th>Study results and mechanisms involved</th><th>Refs.</th></tr></thead><tbody><tr><td>Several</td><td>AML cell line HL60</td><td>Induction of apoptosis. Increase of p27<sup>Kip1</sup>. Activation of cysteine proteases.</td><td>[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td>PSI</td><td>CML, AML, and ALL cell lines</td><td>Induction of apoptosis in all cell lines. Enhanced taxol and cisplatinum cytotoxicity. PSI was more active on leukemic than on normal CD34<sup>+</sup> bone marrow progenitors.</td><td>[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td>Lactacystin</td><td>AML cell line U937</td><td>Lactacystin combined with PKC activator bryostatin enhanced apoptosis.</td><td>[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td>Lactacystin, MG-132</td><td>Primary CLL cells</td><td>Induction of apoptosis in both GC sensitive and resistant cells. Activation of cysteine proteases. Apoptosis is blocked by caspase antagonist zVADfmk. Inhibition of NF-&#x003ba;B.</td><td>[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td>MG-132, LLnL, lactacystin</td><td>AML and ALL cell lines, primary AML cells</td><td>Synergistic interactions between PI and cyclin-dependent kinase inhibitors flavopiridol and roscovitine. Downregulation of XIAP, p21<sup>CIP1</sup>, and Mcl-1.</td><td>[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td>Bortezomib</td><td>Primary CLL cells</td><td>Induction of apoptosis associated with release of SMAC and cytochrome c.</td><td>[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td>Bortezomib</td><td>CML, AML, and ALL cell lines</td><td>Synergistic with flavopiridol. Blockade of the I&#x003ba;B/NF-&#x003ba;B pathway. Activation of the SAPK/JNK cascade. Reduction in activity of STAT3 and STAT5.</td><td>[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td>Bortezomib</td><td>Primary CLL cells</td><td>Dose-dependent cytotoxicity of bortezomib. Additive effect with purine nucleoside analogues cladribine and fludaribine. CLL cells more sensitive than normal lymphocytes.</td><td>[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td>Bortezomib</td><td>AML and ALL cell lines, primary pediatric AML and ALL cells</td><td>Lymphoblastoid, CML and AML cell lines. Bortezomib induced apoptosis and acted at least additive with dexamethasone, vincristine, asparaginase, cytarabine, doxorubicin, geldanamycin, HA14.1, and trichostatin A.</td><td>[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td>Bortezomib</td><td>AML cell lines</td><td>Synergistic with tipifarnib. The combination overcomes cell adhesion-mediated drug resistance.</td><td>[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td>Bortezomib</td><td>Pediatric ALL xenocraft model</td><td>
<italic>In vitro</italic> and <italic>in vivo</italic> activity of bortezomib against primary pediatric ALL cells in a xenocraft mouse model.</td><td>[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td>Bortezomib, PSI</td><td>CML and AML cell lines</td><td>PSI enhanced toxicity of daunoblastin, taxol, cisplatinum, and bortezomib. PSI and bortezomib suppressed clonogenic potential of AML and CML more than that of normal bone marrow (NBM) progenitors. Bortezomib inhibited the clonogenic potential of CML and NBM more effectively.</td><td>[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td>Carfizomib</td><td>Primary AML and ALL cells</td><td>Inhibits proliferation and induces apoptosis AML, inhibits proliferation in ALL.</td><td>[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td>Carfilzomib, bortezomib</td><td>AML cell lines and primary AML cells</td><td>Synergistic effect on proteotoxic stress together with the protease inhibitors ritonavir, nelfinavir, saquinavir, and lopinavir.</td><td>[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td>Carfilzomib, bortezomib</td><td>ALL cell lines <italic>in vitro</italic> and in xenograft model</td><td>Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemia through MLL-AF4.</td><td>[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td>Carfilzomib</td><td>MM, AML, Burkitt&#x02019;s lymphoma cell lines</td><td>Induces proapoptotic sequelae, including proteasome substrate accumulation, Noxa and caspase 3/7 induction, and phospho-eIF2&#x003b1; suppression.</td><td>[<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>Marizomib</td><td>ALL, AML, and CML cell lines and in xenograft model</td><td>Induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors.</td><td>[<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td>Marizomib, bortezomib</td><td>AML and ALL cell lines</td><td>Anti-leukemic activity, synergistic in combination with bortezomib.</td><td>[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td>ONX 0914</td><td>AML and ALL cell lines</td><td>Growth inhibition, proteasome inhibitor-induced apoptosis, activation of PARP cleavage and accumulation of polyubiquitinated proteins.</td><td>[<xref ref-type="bibr" rid="CR16">16</xref>]</td></tr><tr><td>PR-924</td><td>AML and ALL cell lines</td><td>Growth inhibition, immune proteasome inhibition, apoptosis, activation of PARP cleavage.</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td>Ixazomib</td><td>Primary CLL cells</td><td>Annexin-V staining, PARP1 and caspase-3 cleavage and an increase in mitochondrial membrane permeability, apoptosis was only partially blocked by the pan-caspase inhibitor z-VAD-fmk.</td><td>[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr></tbody></table><table-wrap-foot><p>Updated from Franke et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</p><p>Abbreviations: <italic>PSI</italic> N-carbobenzoxy-L-isoleucyl-L-&#x003b3;-t-butyl-L-glutamyl-L-alanyl-L-leucinal, <italic>LLnV</italic> N-Carbobenzoxy-L-leucyl-L-norvalinal, <italic>LLnL</italic> N-acetylleucylleucylnorleucinal, <italic>MG-132</italic> Carbobenzoxy-L-leucyl-L-leucyl-leucinal, <italic>GC</italic> glucocorticoid, <italic>PKC</italic> protein kinase C</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec3"><title>Markers for PI (BTZ) sensitivity/resistance in leukemia cell lines</title><p id="Par8">As with any new treatment strategy, selection of patients who will benefit from the treatment is essential. With respect to PIs, studies with leukemia cell lines can help to define markers for response, long-term efficacy, and emergence of resistance to PIs. Resistance mechanisms often reveal critical processes such as targeted and compensatory mechanisms that leukemia cells harbor to overcome the effects of PIs. A large number of studies have followed the approach of exposing leukemia cells to stepwise increasing concentrations of PIs (mostly BTZ) and characterize cells with acquired resistance [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>]. Figure <xref rid="Fig3" ref-type="fig">3</xref> depicts an overview of molecular mechanisms of resistance in PI/BTZ-resistant leukemia cell lines [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. The most common mechanisms are discussed below.<fig id="Fig3"><label>Fig. 3</label><caption><p>Overview of known molecular mechanisms involved in BTZ resistance. <bold>a</bold> Proteasome related resistance: relative down regulation of immunoproteasome as compared to constitutive proteasome (1) together with absolute upregulation of the constitutive proteasome (2) and mutation in the &#x003b2;5 subunit of the proteasome (3). <bold>b</bold> Alternative stress handling: upregulation of heat shock proteins (4) or changes in redox metabolism (5) which can prevent oxidative stress. Alternative handling ubiquitinated protein: exocytosis of ubiquitinated proteins in MARCKS-associated vesicles (6), and protein degradation through autophagy (7). <bold>c</bold> Activation pro-survival signaling: intrinsic activation of pro-survival pathways, e.g., AKT, NF&#x003ba;B, or MET (8) or through stimulation by direct interaction with stromal cells (9) or indirectly through soluble growth factors or interleukins (10). <bold>d</bold> Decreased apoptosis: downregulation (11) or mutation (12) of pro-apoptotic proteins. Finally, <bold>e</bold>, extrusion of BTZ <italic>via</italic> multidrug resistance efflux pump MDR1/Pgp (minor effect, more pronounced in CFZ resistance) (13). CP, constitutive proteasome; IP, immunoproteasome; MDR1, multidrug resistance protein 1; HSP, heat shock proteins; IGF1, insulin-like growth factor 1; IL, interleukin</p></caption><graphic xlink:href="10555_2017_9699_Fig3_HTML" id="MO3"/></fig>
</p><sec id="Sec4"><title>Upregulation of proteasomal subunits</title><p id="Par9">Upregulation of the primary target is a well-known response of cells exposed to drugs. Likewise, upregulation of proteasomal subunits, and the &#x003b2;5 subunit in particular, is frequently observed in BTZ-resistant leukemia cell lines (reviewed in [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]) indicating its role in BTZ resistance. Consistently, CGH analysis of BTZ-resistant cell lines revealed amplification of the <italic>PSMB5</italic> gene with variability in size and extent of the amplification of chromosome 6 [<xref ref-type="bibr" rid="CR73">73</xref>]. Remarkably, immunoproteasome subunit levels are often found to be decreased in BTZ-resistant leukemia cell lines [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. The resulting decrease in immuno- / constitutive proteasome ratio and alterations in subunit composition has been linked to a diminished BTZ sensitivity [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Interferon gamma (IFN&#x003b3;) is an efficient inducer of immunoproteasome expression and partly restored BTZ sensitivity in BTZ-resistant leukemia cells [<xref ref-type="bibr" rid="CR16">16</xref>]. Beyond BTZ-resistant cells, IFN&#x003b3; also enhanced BTZ sensitivity in a panel of B cell lines by 50% [<xref ref-type="bibr" rid="CR76">76</xref>]. Together, these data underscore the importance of immuno- and constitutive proteasome subunit composition in BTZ sensitivity and resistance in leukemia cells.</p></sec><sec id="Sec5"><title><italic>PSMB5</italic> mutations</title><p id="Par10">Molecular analysis of the proteasome subunits of PI-resistant leukemia cell lines revealed several mutations in exon 2 of the <italic>PSBM5</italic> gene encoding the highly conserved binding pocket region for PIs within the &#x003b2;5 subunit of the proteasome. This highly conserved region appears to be a mutation &#x0201c;hot spot&#x0201d; when cells are exposed to BTZ for a prolonged period. Figure <xref rid="Fig4" ref-type="fig">4</xref> shows an overview of <italic>PSMB5</italic> mutations in PI-resistant cell lines, including non-hematological malignancies.<fig id="Fig4"><label>Fig. 4</label><caption><p>Clustering of <italic>PSMB5</italic> mutations in several BTZ-resistant <italic>in vitro</italic> model systems [<xref ref-type="bibr" rid="CR68">68</xref>&#x02013;<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR77">77</xref>&#x02013;<xref ref-type="bibr" rid="CR81">81</xref>]</p></caption><graphic xlink:href="10555_2017_9699_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par11">All mutations result in amino acid alteration in, or in the close vicinity of, the PI binding pocket [<xref ref-type="bibr" rid="CR82">82</xref>]. In fact, except for the A247G mutation which introduces a Thr21Ala substitution, all mutations result in amino acid alterations in the S1 pocket of the &#x003b2;5 subunit with Ala49 being the most affected amino acid. This specificity pocket is a highly conserved part of the subunit and responsible for recognizing the peptide bond of the substrate. It is also the site that has to be cleaved and determines the specificity as well as facilitates the binding of the P1 side chain of BTZ [<xref ref-type="bibr" rid="CR82">82</xref>]. <italic>In silico</italic> analysis provided evidence for hindered binding of BTZ by the majority of the mutations, including the Thr21Ala amino acid alteration positioned outside of the S1 pocket but within the BTZ binding pocket [<xref ref-type="bibr" rid="CR82">82</xref>]. The only exceptions were the Met45Ile and Met45Val substitutions, which do not directly interact with BTZ. However, Met45 is known to contribute to the specificity of the S1 pocket and upon binding, Met45 undergoes a conformational change and shifts the direction of its side chain towards Cys52 vicinity. Alterations in this amino acid might therefore hinder this conformational change and contribute as well to decreased BTZ binding. Docking the LLVY-AMC substrate <italic>in silico</italic> in the crystal structure of the &#x003b2;5 subunit supported the hypothesis of decreased binding of the substrate in the mutated binding pocket.</p><p id="Par12">There are two strong indications that <italic>PSMB5</italic> mutations are related to PI resistance. First, from marine biology studies, characterization of proteasome subunits of the PI Salinosporamide A (NPI-0052, Marizomib) producing actinobacterium <italic>Salinispora tropica</italic> revealed the same Ala49Val and Met45Phe mutations in the &#x003b2;5 subunit homologue as in BTZ-resistant leukemia cells. In <italic>S. tropica</italic>, these mutations conferred &#x0201c;self-resistance&#x0201d; to Salinosporamide A [<xref ref-type="bibr" rid="CR80">80</xref>]. Second, acquired resistance to the immunoproteasome inhibitor in PR-924 was not associated with any mutation(s) in immunoproteasome subunits, but rather provoked <italic>PSMB5</italic> mutations, i.e., Met45Ile, Ala49Thr, and Met45Val [<xref ref-type="bibr" rid="CR29">29</xref>]. Taken together, inhibition of the &#x003b2;5 subunit is essential for the anti-leukemia effect of PIs and <italic>PSMB5</italic> mutations emerging after prolonged PI treatment attenuate the inhibitory potency and confer resistance in leukemia cells. <italic>PSMB5</italic> mutations have thus far not been identified in patients receiving PI therapy and it has been challenged whether these mutations hold clinical relevance for PI resistance. However, until now, longstanding treatment with the first-generation PI was hardly applied in clinical practice. This may change with the introduction of second-generation and oral PI&#x02019;s allowing for long-term treatment.</p></sec><sec id="Sec6"><title>Alternative protein disposal</title><p id="Par13">Gene expression profiling of BTZ-resistant leukemia cells identified myristoylated alanine-rich C-kinase substrate (MARCKS) as being highly upregulated. MARCKS is an 80-kDa protein that is involved in multiple exocytosis pathways (reviewed in [<xref ref-type="bibr" rid="CR83">83</xref>]). In fact, in BTZ-resistant leukemia cells, MARCKs protein co-localized with intracellular vesicles that contained polyubiquitinated proteins and which were formed upon exposing cells to increasing concentrations of BTZ. The ubiquitin-containing vesicles have been described before [<xref ref-type="bibr" rid="CR84">84</xref>], and in co-cultures, it was shown that after extrusion of the vesicles, they were taken up in proteasome-proficient acceptor cells [<xref ref-type="bibr" rid="CR73">73</xref>]. MARCKs may thus contribute to BTZ resistance by facilitating exocytosis-mediated extrusion of polyubiquitinated proteins to overcome proteolytic stress imposed by BTZ. MARCKs upregulation is not restricted to BTZ-resistant leukemia cells, but was also observed in leukemia cells with acquired resistance to second-generation PI, e.g., Salinosporamide A (Marizomib) and the immunoproteasome inhibitor PR924.</p><p id="Par14">Another alternative protein disposal that is often related to drug resistance is autophagy. This process has been linked to BTZ resistance in several tumor models [<xref ref-type="bibr" rid="CR85">85</xref>&#x02013;<xref ref-type="bibr" rid="CR91">91</xref>], although it was not indicated in MARCKs overexpressing PI-resistant leukemia cells [<xref ref-type="bibr" rid="CR73">73</xref>]. Inhibition of autophagy through different mechanisms including calpain inhibitor [<xref ref-type="bibr" rid="CR86">86</xref>], downregulation of heat shock protein B8 (HSPB8) [<xref ref-type="bibr" rid="CR87">87</xref>], B cell lymphoma 2-interacting mediator of cell death (BIM) upregulation [<xref ref-type="bibr" rid="CR90">90</xref>], tipifarnib [<xref ref-type="bibr" rid="CR85">85</xref>], or (hydroxy)chloroquine [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>] increased BTZ sensitivity in a MM model. In addition, histone deacetylase (HDAC) inhibitors can block autophagy by disrupting aggresome formation, the process that precedes autophagy [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Interestingly, the E3 ligase, TRAF6, links the NFkB pathway to autophagy [<xref ref-type="bibr" rid="CR96">96</xref>] and it was shown that BTZ-resistant AML cells were sensitized by downregulating TRAF 6 [<xref ref-type="bibr" rid="CR97">97</xref>]. Despite the potential impact of autophagy on BTZ resistance, the extent of involvement of this process in leukemia cells needs further exploration.</p></sec><sec id="Sec7"><title>Activation of pro-survival pathways</title><p id="Par15">Analogous to resistance to many anti-leukemia drugs, PI resistance has also been associated with the activation of pro-survival pathways. The most extensively described is the association with the NF&#x003ba;B survival pathway (for AML reviewed in [<xref ref-type="bibr" rid="CR98">98</xref>]). As PI result in the stability of the inhibitor of NF&#x003ba;B (I&#x003ba;B), this survival pathway is inhibited by exposure to PI. Intrinsically resistant leukemia cells (e.g., stem cells) have a constitutively activated NF&#x003ba;B pathway and the combination of BTZ with NF&#x003ba;B inhibition by the IKK inhibitor BMS-345541, enhanced the kill of AML stem cells [<xref ref-type="bibr" rid="CR99">99</xref>]. Although the interaction between NF&#x003ba;B and PI resistance is clearly established for MM and other tumor types [<xref ref-type="bibr" rid="CR100">100</xref>&#x02013;<xref ref-type="bibr" rid="CR104">104</xref>], the data of relevance for leukemia is limited. Besides NF&#x003ba;B, the pro-survival pathways <italic>via</italic> AKT/mTOR [<xref ref-type="bibr" rid="CR105">105</xref>&#x02013;<xref ref-type="bibr" rid="CR107">107</xref>] and insulin-like growth factor 1 (IGF-1) [<xref ref-type="bibr" rid="CR108">108</xref>&#x02013;<xref ref-type="bibr" rid="CR110">110</xref>] have also been described to confer BTZ resistance and may affect the interaction of leukemia cells with (stromal) cells in their micro-environment.</p></sec><sec id="Sec8"><title>X-box binding protein 1 (XBP1)</title><p id="Par16">X-box binding protein 1 (XBP1) is a transcription factor involved in the unfolded protein response. In addition, it is important for the differentiation of plasma cells. In this respect, XBP1 expression has been linked to BTZ resistance [<xref ref-type="bibr" rid="CR111">111</xref>] and survival [<xref ref-type="bibr" rid="CR112">112</xref>] in MM. In leukemia, this pathway may also be related to PI resistance; however, data are currently lacking. Due to the role of XBP1 in B cell differentiation, this factor may be particularly relevant for B-ALL and warrants further study.</p></sec><sec id="Sec9"><title>Drug efflux transporters</title><p id="Par17">Drug efflux transporters of the ATP-binding cassette protein family have been explored for their role in PI resistance. P-glycoprotein (Pgp, ABCB1), as one of its main representatives only marginally contributes to BTZ efflux [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR113">113</xref>], but is of relevance for second-generation PIs such as CFZ and the immunoproteasome inhibitor ONX-0914 as these PIs are <italic>bona fide</italic> substrates for Pgp [<xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>]. Notably, BTZ can downregulate Pgp expression and this manner indirectly attenuate drug resistance [<xref ref-type="bibr" rid="CR116">116</xref>]. There is no evidence that BTZ and other second-generation PIs are substrates for other drug efflux transporters, e.g., multidrug resistance-associated protein 1&#x02013;5 (MRP1&#x02013;5, ABCC1&#x02013;5) or breast cancer resistance protein (BCRP, ABCG2); hence, a role in PI resistance is not anticipated [<xref ref-type="bibr" rid="CR114">114</xref>].</p></sec></sec><sec id="Sec10"><title>Markers for PI (BTZ) sensitivity/resistance in primary leukemia samples</title><p id="Par18">Although <italic>in vitro</italic> models are valuable tools to identify possible mechanisms of BTZ resistance, assessment of the relevance for the clinic requires validation in <italic>ex vivo</italic> studies using primary patient samples. Preferably, this is studied in add-on studies of clinical trials that include BTZ in the treatment protocol. The potential role of three markers for PI (BTZ) sensitivity and/or resistance in leukemia samples is discussed below.</p><sec id="Sec11"><title>Proteasome levels and subunit composition</title><p id="Par19">Add-on studies of clinical trials in leukemia are limited and most data for PIs are obtained from MM studies. These studies demonstrated besides proteasome expression levels, the proteasome subunit composition is important for response [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. Although upregulation of the proteasome was not related to resistance in mantle cell lymphoma (MCL) patients [<xref ref-type="bibr" rid="CR119">119</xref>], studies in leukemia indicated a possible correlation between higher 20S protein expression and BTZ sensitivity [<xref ref-type="bibr" rid="CR120">120</xref>]. In particular, studies by Niewerth et al. (2013) showed that lower &#x003b2;5 subunit expression correlated with increased <italic>ex vivo</italic> sensitivity for proteasome inhibitors in pediatric AML and ALL samples. In addition, the sensitivity for BTZ in AML cells inversely correlated with the ratios between immunoproteasome subunits over constitutive subunits, specifically &#x003b2;1i/&#x003b2;1 and &#x003b2;2i/&#x003b2;2, and a trend for &#x003b2;5i/&#x003b2;5. ALL cells showed higher sensitivity to BTZ as compared to AML cells. Although for ALL no significant correlations were revealed with BTZ sensitivity, they featured a higher &#x003b2;2i/&#x003b2;2 ratio and trends of a higher &#x003b2;1i/&#x003b2;1 ratio as compared to AML samples. Together, these data support the notion that a relative high immuno- / constitutive proteasome ratio promotes BTZ sensitivity. These data were confirmed in AML and ALL samples obtained from two pediatric clinical COG trials (AAML07P1 and AALL07P1) in which BTZ treatment was incorporated [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. After further validation in larger studies, assessment of immunoproteasome over constitutive proteasome ratios may be used as biomarkers of response to PIs.</p></sec><sec id="Sec12"><title>PSMB5 mutations</title><p id="Par20">
<italic>PSMB5</italic> mutations observed in BTZ-resistant hematological cell lines were as yet not identified in clinical samples. The mutations found in the cell line models do not represent SNPs found in the general population. Wang et al. sequenced the PSMB5 gene in a large cohort of healthy persons and 61 MM patients after BTZ treatment [<xref ref-type="bibr" rid="CR121">121</xref>]. No SNPs were found in the exon 2 of the <italic>PSMB5</italic> gene neither in the general population nor in MM patients. Of interest, polymorphisms that influenced <italic>PSMB5</italic> gene expression were observed, but these did not correlate with BTZ response. It should be taken into account that sequence analysis in one third of the MM patients was performed only on whole blood and not on isolated malignant plasma cells, which may have influenced the sensitivity of the analysis. In addition, it was not stated how many resistant patients were included. More recently, Lichter et al. sequenced the <italic>PSMB5</italic> gene in blood samples of MM patients included in the APEX trial in which patients were treated with either BTZ or dexamethasone [<xref ref-type="bibr" rid="CR122">122</xref>]. No <italic>PSMB5</italic> mutations were identified in this group. Although sample size of this group was limited, the data suggest that <italic>PSMB5</italic> mutations do not represent a leading cause of acquired BTZ resistance in investigated MM protocols. Whether this holds true for leukemia or MM with long-term BTZ maintenance therapy is yet to be determined. Lastly, as a preliminary account, Barrio et al. (2016) reported <italic>PSMB5</italic> mutations in subclones of CD138+ cells of a single MM patient after a therapy [<xref ref-type="bibr" rid="CR123">123</xref>]. Since the subclonal frequencies were low, this poses analytical challenges to detect these subclones. Also in leukemia, it is established that there is substantial oligoclonality in mutational status of cells within the leukemia. The cells with the specific mutations tendering growth advantage are probably selected to grow out and develop a (drug resistant) relapse [<xref ref-type="bibr" rid="CR124">124</xref>], so also in leukemia patients subclonal analysis may reveal additional mutations.</p></sec><sec id="Sec13"><title>MARCKS</title><p id="Par21">Upregulation of MARCKs protein expression emerged as a marker for BTZ- and second-generation PI-resistant leukemia cell lines [<xref ref-type="bibr" rid="CR73">73</xref>]. To test whether this upregulation might be a prognostic marker for clinical BTZ resistance, MARCKs expression was examined in 44 primary ALL patient samples obtained from the clinical COG trial AALL07P1 using combination chemotherapy including BTZ. A trend (<italic>p</italic>&#x000a0;=&#x000a0;0.07) was seen in the inverse correlation between MARCKS expression and clinical response. Since the samples were obtained in the setting of a clinical trial using combination therapy, a direct correlation between BTZ response and MARCKS expression cannot be made. However, these findings are consistent with data from Micallef et al. who showed MARCKS protein upregulation in a small group of BTZ-resistant MM patients [<xref ref-type="bibr" rid="CR125">125</xref>] and Yang et al. who identified MARCKS upregulation as a resistance marker in primary MM samples [<xref ref-type="bibr" rid="CR126">126</xref>]. These studies encourage a prospective validation of the possible prognostic role of MARCKS in leukemia.</p></sec></sec><sec id="Sec14"><title>Clinical trials with proteasome inhibitors in leukemia</title><p id="Par22">The efficacy and safety of PIs in MM have already been extensively reviewed [<xref ref-type="bibr" rid="CR127">127</xref>]. For leukemia, an overview of phase I/II clinical studies of PI as single agent and combination therapy in adult and pediatric leukemia is presented in Table <xref rid="Tab3" ref-type="table">3</xref>. An overview of ongoing phase II/III clinical trials with BTZ (combination) therapy involving pediatric leukemia patients and adult leukemia is shown in Table <xref rid="Tab4" ref-type="table">4</xref> and Table <xref rid="Tab5" ref-type="table">5</xref>, respectively. In addition, ongoing clinical trials with second-generation PIs (mainly CFZ and IXA) are depicted in Table <xref rid="Tab6" ref-type="table">6</xref>. The outcome for clinical efficacy included stable disease, progressive disease, complete/partial remission, and mortality. In all studies, infections and neutropenia were common adverse drug reactions (ADRs). Neurologic ADRs were also common in all studies with BTZ, including neuropathy. Interestingly, BTZ might also have some protective effects as well, as it has been reported to prevent muscle wasting [<xref ref-type="bibr" rid="CR148">148</xref>], which can be induced by cancer cachexia [<xref ref-type="bibr" rid="CR149">149</xref>] but this has not yet been reported in a clinical setting. Two studies were conducted with CFZ [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>] and less ADRs were found in these studies including the absence of neurologic ADRs. Moreover, no dose-limiting toxicities (DLT) were found indicating a better safety profile. Importantly, the clinical response to CFZ in these studies was also better than reported for BTZ treatment.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Published clinical studies of proteasome inhibitors in leukemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study drugs</th><th>Cohort</th><th>Number</th><th>Phase</th><th>Study results and mechanisms involved</th><th>Refs.</th></tr></thead><tbody><tr><td>BTZ</td><td>Several hematologic malignancies</td><td>27</td><td>I</td><td>Bortezomib was given twice weekly for 4&#x000a0;weeks every 6&#x000a0;weeks. The MTD was 1.04&#x000a0;mg/m<sup>2</sup>. CR in 1 MM patient. PR in 1 patient with MCL and 1 with FL.</td><td>[<xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td>BTZ</td><td>Refractory or relapsed acute leukemia</td><td>15</td><td>I</td><td>Bortezomib was given twice weekly for 4&#x000a0;weeks every 6&#x000a0;weeks. The MTD was 1.25&#x000a0;mg/m<sup>2</sup>. No &#x02265;grade 3 toxicities. 5 patients showed hematological improvement. No CR achieved.</td><td>[<xref ref-type="bibr" rid="CR129">129</xref>]</td></tr><tr><td>BTZ, PegLD</td><td>AML, MM, and NHL</td><td>42</td><td>I</td><td>Bortezomib was given on days 1, 4, 8, and 11 and PedLD on day 4. MTD of BTZ 1.3&#x000a0;mg/m<sup>2</sup>. No significant pharmacokinetic and pharmacodynamic interactions between bortezomib and PegLD. 16 of 22 MM patients achieved CR, near-CR or PR. 1 CR and 1 PR in NHL patients. 2 of 2 AML patients achieved a PR.</td><td>[<xref ref-type="bibr" rid="CR130">130</xref>]</td></tr><tr><td>BTZ</td><td>Recurrent childhood ALL, AML, blastic phase CML, M3</td><td>12</td><td>I</td><td>Bortezomib was administered twice weekly for 2&#x000a0;weeks followed by a 1-week rest. MTD of bortezomib was 1.3&#x000a0;mg/m<sup>2</sup>/dose. 5 patients were fully evaluable. DLT&#x02019;s occurred in 2 patients at the 1.7&#x000a0;mg/m<sup>2</sup> dose level. No OR achieved.</td><td>[<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td>BTZ, IDA, AraC</td><td>AML</td><td>31</td><td>I</td><td>Addition of BTZ to AML induction chemotherapy. Bortezomib added on days 1, 4, 8, and 11. 19 CR, 3 CRp, 2 PR and 7 no response. BTZ was well-tolerated up to 1.5&#x000a0;mg/m<sup>2</sup>.</td><td>[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td>BTZ, VCR, DEX, PegAspa, DOX</td><td>Recurrent childhood ALL</td><td>10</td><td>I</td><td>Combination of bortezomib (1.3&#x000a0;mg/m<sup>2</sup>) with ALL induction therapy is active with acceptable toxicity. 6 patients achieved CR.</td><td>[<xref ref-type="bibr" rid="CR133">133</xref>]</td></tr><tr><td>BTZ, VCR, DEX, PegAspa, DOX</td><td>Recurrent childhood ALL</td><td>22</td><td>II</td><td>14 patients achieved CR, and 2 achieved CRp, 3 patients died from bacterial infections, 2 of 2 included T cell ALL patients did not respond.</td><td>[<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td>BTZ, tipifarnib</td><td>Relapsed or refractory ALL(26) or AML (1)</td><td>27</td><td>I</td><td>Combination well tolerated. 2 patients achieved CRp and 5 SD.</td><td>[<xref ref-type="bibr" rid="CR135">135</xref>]</td></tr><tr><td>BTZ, DNR, AraC</td><td>AML (age &#x0003e;&#x000a0;65)</td><td>95</td><td>I/II</td><td>Combination was tolerated. 62 patients achieved CR and 4 patients CRp.</td><td>[<xref ref-type="bibr" rid="CR136">136</xref>]</td></tr><tr><td>BTZ, 17-AAG</td><td>Relapsed or refractory AML</td><td>11</td><td>I</td><td>The combination of 17-AAG and BTZ led to toxicity without measurable response in patients with relapsed or refractory AML.</td><td>[<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td>BTZ, DAC</td><td>Poor-risk AML</td><td>19</td><td>I</td><td>Combination was tolerable and active in this cohort of AML patients; 7 of 19 patients had CR or CRi. 5 of 10 patients &#x0003e;&#x000a0;65&#x000a0;years had CR.</td><td>[<xref ref-type="bibr" rid="CR138">138</xref>]</td></tr><tr><td>BTZ, LEN</td><td>14 MDS/CMML<break/>9 AML</td><td>23</td><td>I</td><td>MTD of BTZ 1.3&#x000a0;mg/m<sup>2</sup> was tolerable in this regimen. Responses were seen in patients with MDS and AML. Two fatal infections occurred.</td><td>[<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td>BTZ, IDA</td><td>Relapsed AML (7) or AML &#x0003e;&#x000a0;60&#x000a0;years (13)</td><td>20</td><td>I</td><td>4 patients achieved complete remission. 1 treatment-related death. Overall the combination was well tolerated.</td><td>[<xref ref-type="bibr" rid="CR140">140</xref>]</td></tr><tr><td>BTZ, AZA</td><td>Relapsed or refractory AML</td><td>23</td><td>I</td><td>Dose of 1.3&#x000a0;mg/m<sup>2</sup> BTZ was reached without dose-limiting toxicities. 5 out of 23 patients achieved CR.</td><td>[<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr><tr><td>BTZ, MIDO <italic>vs</italic> BTZ, MIDO, DHAD, etoposide, AraC</td><td>Relapsed/refractory AML</td><td>21</td><td>I</td><td>56.5% CR rate and 82.5% overall response rate (CR + CR with incomplete neutrophil or platelet count recovery). Combination is active but is associated with expected drug-related toxicities. DLTs were peripheral neuropathy, decrease in ejection fraction and diarrhea.</td><td>[<xref ref-type="bibr" rid="CR142">142</xref>]</td></tr><tr><td>CFZ + dexamethasone</td><td>Refractory or relapsed acute leukemia</td><td>18</td><td>I</td><td>CFZ was given twice weekly for 4&#x000a0;weeks with a maximal of 6&#x000a0;cycles. Prior to CFZ dexamethasone was given. The MTD was not established, because no DLTs were observed (36&#x02013;46&#x000a0;mg/m<sup>2</sup>). PR in 2/10 patients and 4/10 SD.</td><td>[<xref ref-type="bibr" rid="CR143">143</xref>]</td></tr><tr><td>CFZ + dexamethasone</td><td>Previously treated patient with CLL or SLL</td><td>19</td><td>I</td><td>CFZ was given twice weekly for 3&#x000a0;weeks in a 28-day cycle. Prior to CFZ dexamethasone was given. No DLTs observed and all available patients for evaluation had SD (including patients with Del(17p13.1) and fludarabine-resistant disease.</td><td>[<xref ref-type="bibr" rid="CR144">144</xref>]</td></tr><tr><td>BTZ, cytarabine, idarubicin <italic>vs</italic> BTZ, cytarabine etoposide</td><td>Children with relapsed, refractory, or secondary AML</td><td>37</td><td>II</td><td>BTZ, 1 or 1.3&#x000a0;mg/m<sup>2</sup>, was given at days 1, 4, and 8 in combination with idarubicin and cytarabine (arm A) or with etoposide and high dose cytarabine (arm B). Hypokalemia incidence was high, 17%. Four deaths occur, 3 infectious deaths and one from PD. Both arms failed to meet predetermined efficacy thresholds (CRi was not included). Arm A: CR = 21.4%, CRp + CRi = 35.6%, PR = 14.3%. Arm B: CR = 34.8%, CRp + CRi = 13% and one death.</td><td>[<xref ref-type="bibr" rid="CR145">145</xref>]</td></tr><tr><td>BTZ</td><td>Relapsed/refractory ATL</td><td>15</td><td>II</td><td>BTZ, 1.3&#x000a0;mg/m<sup>2</sup>, was given at days 1, 4, 8, and 11. After stage 1, all patients discontinued treatment (PD = 11, AEs = 3) and the study was terminated because BTZ was not considered promising enough as a single agent. 12 patients had Gr 3/4 drug-related AEs of which 2 Gr3/4 peripheral neuropathy. Overall responses: PR = 1, SD = 5. ORR = 6.7%, PFS = 38&#x000a0;days (8&#x02013;122).</td><td>[<xref ref-type="bibr" rid="CR146">146</xref>]</td></tr><tr><td>BTZ, DEX, DOX <italic>vs</italic> BTZ, DEX, cyclophosphamide</td><td>Newly diagnosed primary plasma cell leukemia</td><td>39</td><td>II</td><td>Four alternating cycles of BTZ (1.3&#x000a0;mg/m<sup>2</sup> on days 1, 4, 8, and 11), DEX plus DOX, or cyclophosphamide was given. 35 patients completed the 4&#x000a0;cycles. ORR = 69%, CR = 10%, VGPR = 26%, PR = 23%. 10 were refractory to the induction phase, and 2 deaths due to sepsis occur. 25 patients underwent HDM/ASCT and 1 a syngeneic allograft. After ASCT: ORR = 92% CR = 34%, VGPR = 38%, PR = 16%, PD = 8%. In the intention-to-treat population, the median PFS = 15.1&#x000a0;months and overall survival = 36.3&#x000a0;months.</td><td>[<xref ref-type="bibr" rid="CR147">147</xref>]</td></tr></tbody></table><table-wrap-foot><p>Updated from Franke et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</p><p>Abbreviations: Study outcome: <italic>MTD</italic> maximum tolerated dose, <italic>DLT</italic> dose-limiting toxicities, <italic>CR</italic> complete response, <italic>CRi</italic> incomplete remission, <italic>CRp</italic> CR with incomplete platelet recovery, <italic>PR</italic> partial response, <italic>OR</italic> objective response, <italic>SD</italic> stable disease, <italic>PFS</italic> progression-free survival, <italic>EFS</italic> event-free survival, <italic>OS</italic> overall survival. Malignancies<underline>:</underline>
<italic>MCL</italic> mantle cell lymphoma, <italic>FL</italic> follicular lymphoma, <italic>NHL</italic> non-Hodgkin lymphoma. Drugs<underline>:</underline>
<italic>17-AAG</italic> 17-N-Allylamino-17-Demethoxygeldanamycin, <italic>AraC</italic> cytarabine, <italic>AZA</italic> azacitidine, <italic>BTZ</italic> bortezomib, <italic>CFZ</italic> carfilzomib, <italic>DAC</italic> decitabine, <italic>DEX</italic> dexamethasone, <italic>DHAD</italic> mitoxantrone, <italic>DNR</italic> daunorubicin, <italic>DOX</italic> doxorubicin, <italic>IDA</italic> idarubicin, <italic>LEN</italic> lenalidomide, <italic>PegLD</italic> pegylated liposomal doxorubicin, <italic>PegAspa</italic> pegylated L-asparaginase, <italic>VCR</italic> vincristine</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Ongoing and unpublished clinical trials of bortezomib in acute leukemia which include pediatric patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study drugs</th><th>Time period</th><th>Number</th><th>Phase</th><th>Cohort</th><th>Age</th><th>Sponsor</th><th>Clinical trial identifier</th></tr></thead><tbody><tr><td>BTZ + intensive reinduction chemotherapy</td><td>Mar 2009<break/>Sept 2014</td><td>60</td><td>II</td><td>Relapsed ALL</td><td>1&#x02013;31</td><td>National Cancer Institute (USA)</td><td>NCT00873093</td></tr><tr><td>BTZ, DEX, VCR, MTX</td><td>Sep 2009<break/>Jul 2014</td><td>24</td><td>II</td><td>Relapsed/refractory ALL</td><td>0.5&#x02013;19</td><td>Erasmus Medical Center (Rotterdam, The Netherlands)</td><td>NTR1881<sup>a</sup>
</td></tr><tr><td>BTZ, ATO</td><td>May 2013<break/>May 2018</td><td>30</td><td>II</td><td>Relapsed acute promyelocytic leukemia (APL)</td><td>1&#x02013;75</td><td>Christian Medical College (Vellore, India)</td><td>NCT01950611</td></tr><tr><td>Standard leukemia chemotherapy &#x000b1; BTZ</td><td>Apr 2014<break/>Feb 2019</td><td>1400</td><td>III</td><td>T cell ALL or stages II&#x02013;IV T cell lymphoblastic lymphoma</td><td>2&#x02013;30</td><td>National Cancer Institute (USA)</td><td>NCT02112916</td></tr><tr><td>BTZ, SAHA + reinduction chemotherapy</td><td>Apr 2015<break/>Apr 2019</td><td>30</td><td>II</td><td>Refractory or relapsed MLL rearranged leukemia</td><td>&#x0003c;&#x000a0;21</td><td>St Jude Children&#x02019;s Research Hospital (Memphis, TN, USA)</td><td>NTC 02419755</td></tr><tr><td>BTZ, PANO + reinduction chemotherapy</td><td>Dec 2015<break/>Apr 2019</td><td>40</td><td>II</td><td>Relapsed T cell leukemia or lymphoma</td><td>&#x0003c;&#x000a0;21</td><td>St Jude Children&#x02019;s Research Hospital (Memphis, TN, USA)</td><td>NCT02518750</td></tr><tr><td>BTZ + induction chemotherapy</td><td>Oct 2015<break/>Oct 2020</td><td>50</td><td>I/II</td><td>Infant leukemia and lymphoblastic lymphoma</td><td>&#x0003c;&#x000a0;1</td><td>St Jude Children&#x02019;s Research Hospital (Memphis, TN, USA)</td><td>NCT02553460</td></tr><tr><td>BTZ + reinduction chemotherapy</td><td>July 2015<break/>Apr 2019</td><td>20</td><td>II</td><td>Refractory or relapsed leukemia and lymphoblastic lymphoma</td><td>1&#x02013;39</td><td>Children&#x02019;s Mercy Hospital (Kansas City)</td><td>NCT02535806</td></tr><tr><td>BTZ + HR reinduction chemotherapy</td><td>Aug 2015<break/>Aug 2018</td><td>250</td><td>II</td><td>High-risk (HR) relapsed ALL</td><td>&#x0003c;&#x000a0;18</td><td>Charit&#x000e9; - Universit&#x000e4;tsmedizin (Berlin, Germany)</td><td>EudraCT number: 2012&#x02013;000810-12<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p>Updated from Franke et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</p><p>Abbreviations: Drugs: <italic>ATO</italic> arsenic trioxide, <italic>BTZ</italic> bortezomib, <italic>DEX</italic> dexamethasone, <italic>MTX</italic> methotrexate, <italic>PANO</italic> panobinostat, <italic>SAHA</italic> vorinostat, <italic>VCR</italic> vincristine</p><p>
<sup>a</sup>Source: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.skion.nl">www.skion.nl</ext-link>
</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Ongoing and unpublished clinical trials of proteasome inhibitors in adult acute leukemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study drugs</th><th>Time period</th><th>Number</th><th>Phase</th><th>Cohort</th><th>Age</th><th>Sponsor</th><th>Clinical trial ID</th></tr></thead><tbody><tr><td>BTZ, DHAD, VP16, AraC</td><td>Jan 2006<break/>Sept 2016</td><td>55</td><td>I/II</td><td>Relapsed/refractory acute leukemia</td><td>&#x0003e;&#x000a0;18</td><td>Thomas Jefferson University (PA, USA)</td><td>NCT00410423</td></tr><tr><td>BTZ, FLAG, IDA</td><td>Apr 2008<break/>Jan 2013</td><td>40</td><td>I/II</td><td>Refractory or relapsed AML</td><td>&#x0003e;&#x000a0;18</td><td>PETHEMA Foundation</td><td>NCT00651781</td></tr><tr><td>BTZ, SAHA, SFN</td><td>Feb 2010<break/>Sept 2016</td><td>38</td><td>I/II</td><td>Poor-risk AML</td><td>&#x0003e;&#x000a0;18</td><td>Indiana University (IN, USA)</td><td>NCT01534260</td></tr><tr><td>BTZ, BEL</td><td>May 2010<break/>Feb 2014</td><td>24</td><td>I</td><td>Relapsed/refractory acute leukemia</td><td>&#x0003e;&#x000a0;18</td><td>Virginia Commonwealth University (VA, USA)</td><td>NCT01075425</td></tr><tr><td>BTZ, NFV</td><td>July 2010<break/>Mar 2013</td><td>18</td><td>I</td><td>Relapsed or progressive advanced hematologic cancer</td><td>&#x0003e;&#x000a0;18</td><td>Swiss Group for Clinical Cancer Research (Switzerland)</td><td>NCT01164709</td></tr><tr><td>BTZ, DHAD, VP16, AraC</td><td>July 2010<break/>May 2014</td><td>34</td><td>I</td><td>Relapsed/refractory AML</td><td>18&#x02013;70</td><td>Case Comprehensive Cancer Center (OH, USA)</td><td>NCT01127009</td></tr><tr><td>Several drugs in randomization arms &#x000b1; BTZ</td><td>June 2011<break/>June 2017</td><td>1250</td><td>III</td><td>Initial AML</td><td>&#x0003e;&#x000a0;29</td><td>National Cancer Institute (USA)</td><td>NCT01371981</td></tr><tr><td>DAC <italic>vs</italic> BTZ, DAC</td><td>Nov 2011<break/>June 2015</td><td>172</td><td>II</td><td>AML</td><td>&#x0003e;&#x000a0;60</td><td>National Cancer Institute (USA)</td><td>NCT01420926</td></tr><tr><td>BTZ, DOX, PegAspa, VCR, DEX, AraC, MTX</td><td>Mar 2013<break/>July 2017</td><td>17</td><td>II</td><td>Relapsed/refractory ALL</td><td>&#x0003e;&#x000a0;18</td><td>National Cancer Institute (USA)</td><td>NCT01769209</td></tr><tr><td>BTZ, SFN, DAC</td><td>July 2013<break/>Dec 2016</td><td>30</td><td>I</td><td>AML</td><td>&#x0003e;&#x000a0;60</td><td>National Cancer Institute (USA)</td><td>NCT01861314</td></tr><tr><td>BTZ, DOX</td><td>Mar 2015<break/>Mar 2017</td><td>30</td><td>II</td><td>AML</td><td>18&#x02013;80</td><td>University of California, Davis (CA, USA)</td><td>NCT01736943</td></tr><tr><td>BTZ, LEN</td><td>Mar 2015<break/>Aug 2018</td><td>24</td><td>I</td><td>Relapsed AML and MDS after Alllo SCT</td><td>&#x0003e;&#x000a0;18</td><td>Massachusetts General Hospital (MA, USA)</td><td>NCT023121</td></tr></tbody></table><table-wrap-foot><p>Updated from Franke et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</p><p>Source: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>
</p><p>Abbreviations: Drugs: <italic>17-AAG</italic> 17-N-Allylamino-17-Demethoxygeldanamycin, <italic>AraC</italic> cytarabine, <italic>BEL</italic> belinostat, <italic>BTZ</italic> bortezomib, <italic>DAC</italic> decitabine, <italic>DEX</italic> dexamethasone, <italic>DHAD</italic> mitoxantrone, <italic>DNR</italic> daunorubicin, <italic>DOX</italic> doxorubicin, <italic>IDA</italic> idarubicin, <italic>FLAG</italic> fludarabine, <italic>Ara-C</italic> cytarabine, <italic>G-CSF</italic> granulocyte colony-stimulating factor, <italic>LEN</italic> lenalidomide, <italic>MTX</italic> methotrexate, <italic>NFV</italic> nelvinavir, <italic>PegLD</italic> pegylated liposomal doxorubicin, <italic>PegAspa</italic> pegylated L-asparaginase, <italic>SAHA</italic> vorinostat, <italic>SFN</italic> sorafenib, <italic>VCR</italic> vincristine, <italic>VP16</italic> etoposide</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab6"><label>Table 6</label><caption><p>Ongoing clinical trials of second-generation proteasome inhibitors in acute leukemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study drugs</th><th>Time period</th><th>Number</th><th>Phase</th><th>Cohort</th><th>Age</th><th>Sponsor</th><th>Clinical trial ID</th></tr></thead><tbody><tr><td>CFZ</td><td>Sept 2010<break/>Jul 2015</td><td>18</td><td>I</td><td>Relapsed/refractory ALL and AML</td><td>&#x0003e;&#x000a0;18</td><td>Washington University School of Medicine (MO, USA)</td><td>NCT01137747</td></tr><tr><td>IXA, DHAD, VP16, AraC</td><td>May 2014<break/>Nov 2017</td><td>30</td><td>I</td><td>Relapsed/refractory AML</td><td>18&#x02013;70</td><td>Case Comprehensive Cancer Center; National Cancer Institute (NCI)</td><td>NCT02070458</td></tr><tr><td>IXA</td><td>Mar 2014<break/>Mar 2016</td><td>16</td><td>II</td><td>Relapsed/refractory AML</td><td>&#x0003e;&#x000a0;18</td><td>Stanford university/National Cancer Institute (NCI)</td><td>NCT02030405</td></tr><tr><td>IXA, DHAD, VP16, AraC</td><td>Oct 2014<break/>Nov 2018</td><td>30</td><td>I</td><td>Relapsed/refractory AML</td><td>18&#x02013;70</td><td>Case Comprehensive Cancer Center (USA)</td><td>NCT 02070458</td></tr><tr><td>CFZ, DEX, DHAD, PegAspa, VCR</td><td>Dec 2014<break/>Jul 2017</td><td>39</td><td>I/II</td><td>Relapsed/refractory AML</td><td>&#x0003c;&#x000a0;18</td><td>Onyx Therapeutics Inc. (CA, USA)</td><td>NCT02303821</td></tr><tr><td>CFZ, CYCLO, VP16</td><td>Jul 2015<break/>Dec 2017</td><td>50</td><td>I</td><td>Relapsed leukemia and solid tumors</td><td>6&#x02013;29</td><td>Phoenix Children&#x02019;s Hospital (AZ, USA)</td><td>NCT 02512926</td></tr><tr><td>IXA + induction and consolidation chemotherapy</td><td>Nov 2015<break/>Feb 2022</td><td>54</td><td>I</td><td>AML</td><td>&#x0003e;&#x000a0;60</td><td>Massachusetts General Hospital (MA, USA)</td><td>NCT02582359</td></tr></tbody></table><table-wrap-foot><p>Updated from Franke et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</p><p>Source: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>
</p><p>Abbreviations: Drugs: <italic>AraC</italic> cytarabine, <italic>CFZ</italic> carfilzomib, <italic>CYCLO</italic> cyclophosphamide, <italic>DEX</italic> dexamethasone, <italic>DHAD</italic> mitoxantrone, <italic>IXA</italic> ixazomib, <italic>VCR</italic> vincristine, <italic>VP16</italic> etoposide</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec15"><title>Future perspectives</title><p id="Par23">This overview of results of PI in leukemia reveals that treatment with PI as monotherapy may not give satisfactory clinical responses. To improve the employability of PI in leukemia, several factors are implied to be considered.</p><sec id="Sec16"><title>Combination strategies</title><p id="Par24">For leukemia, chemotherapy commonly consists of cocktails of different drugs with different mechanisms of actions and different side effects to exert optimal treatment response with achievable dosages. For novel drugs, it is therefore essential that they can be combined with the most effective drugs currently used. Based on the mechanism of action, glucocorticoids are good candidate drugs to be combined with PI. BTZ and dexamethasone showed synergy in <italic>ex vivo</italic> combination studies in primary pediatric ALL samples [<xref ref-type="bibr" rid="CR48">48</xref>] clinically BTZ was combined with induction therapy including dexamethasone, vincristine, PEG-asparaginase, and doxorubicin in relapsed pediatric ALL, showing promising CR rates [<xref ref-type="bibr" rid="CR133">133</xref>, <xref ref-type="bibr" rid="CR134">134</xref>]. Currently, several clinical trials are ongoing (Tables&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> and <xref rid="Tab5" ref-type="table">5</xref>), combining BTZ with several chemotherapy protocols which include the standard chemotherapeutics and novel strategies (heat shock protein inhibitors, HDAC inhibitors, and autophagy inhibitors). Based on preclinical data and expected toxicity profiles of the different drugs, the addition of PI to other chemotherapeutics seems a fruitful strategy. In addition, recently the nuclear transport (XPO1) inhibitor selinexor has been combined with BTZ [<xref ref-type="bibr" rid="CR150">150</xref>] and is currently in a clinical trial for MM (NCT03110562). Whether this is also a relevant strategy for leukemia still has to be established.</p></sec><sec id="Sec17"><title>Second-generation proteasome inhibitors</title><p id="Par25">Despite the successful introduction of BTZ, several drawbacks such as resistance and toxic side effects led to development of second-generation proteasome inhibitors which are at several stages of clinical development (Table <xref rid="Tab6" ref-type="table">6</xref>). Due to promising preclinical studies, the irreversible proteasome inhibitor CFZ has advanced rapidly into the clinic for MM as well as leukemia, and is supposed to be a promising alternative for BTZ and might even overcome BTZ resistance.</p><p id="Par26">Recently, an oral formulation resembling BTZ, ixazomib (MLN9708), has emerged into the clinic, with two clinical trials investigating the efficacy of ixazomib in AML (NCT0230405 and NCT 02070458).</p><p id="Par27">PR-957 (ONX 0914) and PR-924 represent members of a new class of proteasome inhibitors being directed specifically against the immunoproteasome [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. PR-924 demonstrated preclinical efficacy in leukemia and MM [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In addition, <italic>ex vivo</italic> cytotoxicity of PR-957 was shown in primary leukemia samples [<xref ref-type="bibr" rid="CR29">29</xref>]. Since leukemia cells, especially ALL cells, express high levels of immunoproteasome, it might be a good candidate for further clinical development in hematological malignancies.</p><p id="Par28">Development of acquired resistance to the second-generation PIs [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] has to be taken in account as well. Hence, combination therapy is also recommended for the treatment of leukemia with these novel PIs in order to circumvent toxicity and resistance.</p></sec><sec id="Sec18"><title>Biomarkers of clinical response to proteasome inhibitors</title><p id="Par29">The combination of preclinical research and ongoing clinical studies (e.g., add-on studies) will be needed to identify and confirm determinants of resistance and markers for clinical response in order to further personalize the treatment of acute leukemia with PI. Based on accumulating data, prediction of effectivity of PI lies in the composition of the proteasome, in particular the ratio between constitutive- and immunoproteasome subunits. This can either be assessed by measuring protein expression of the different subunits [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR121">121</xref>] or their specific catalytic activities for which several assays are available [<xref ref-type="bibr" rid="CR151">151</xref>, <xref ref-type="bibr" rid="CR152">152</xref>]. In addition, the activity assays can be used for pharmacodynamic monitoring of PI inhibition and duration of inhibition in PBMC&#x02019;s [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>].</p><p id="Par30">Since mutations in the genes encoding proteasome subunits have not been found in primary MM and acute leukemia patient samples either before or after treatment with PI, they are currently not considered potential biomarkers for resistance to proteasomes. However, when patients are treated for prolonged time periods such as the maintenance treatment of elderly MM patients with IXA, they might be acquired. Therefore, add-on studies measuring the mutational status in samples during treatment are currently performed. If mutations are identified, they may be used to monitor acquired resistance to PI. Selecting the patients that benefit from PI treatment and the recognition of PI resistance is indispensable for the optimal implementation of PI in acute leukemia treatment.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>This research was supported by KIKA (children cancer free) and the Egbers Foundation.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terwilliger</surname><given-names>T</given-names></name><name><surname>Abdul-Hay</surname><given-names>M</given-names></name></person-group><article-title>Acute lymphoblastic leukemia: a comprehensive review and 2017 update</article-title><source>Blood Cancer J</source><year>2017</year><volume>7</volume><fpage>e577</fpage><?supplied-pmid 28665419?><pub-id pub-id-type="pmid">28665419</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Kouchkovsky</surname><given-names>I</given-names></name><name><surname>Abdul-Hay</surname><given-names>M</given-names></name></person-group><article-title>Acute myeloid leukemia: a comprehensive review and 2016 update</article-title><source>Blood Cancer J</source><year>2016</year><volume>6</volume><fpage>e441</fpage><?supplied-pmid 27367478?><pub-id pub-id-type="pmid">27367478</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pui</surname><given-names>C-H</given-names></name><name><surname>Carroll</surname><given-names>WL</given-names></name><name><surname>Meshinchi</surname><given-names>S</given-names></name><name><surname>Arceci</surname><given-names>RJ</given-names></name></person-group><article-title>Biology, risk stratification, and therapy of pediatric acute leukemias: an update</article-title><source>Journal of Clinical Oncology</source><year>2011</year><volume>29</volume><fpage>551</fpage><lpage>565</lpage><?supplied-pmid 21220611?><pub-id pub-id-type="pmid">21220611</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Jabbour</surname><given-names>EJ</given-names></name></person-group><article-title>Adult acute lymphoblastic leukemia</article-title><source>Mayo Clinic Proceedings</source><year>2016</year><volume>91</volume><fpage>1645</fpage><lpage>1666</lpage><?supplied-pmid 27814839?><pub-id pub-id-type="pmid">27814839</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhury</surname><given-names>SS</given-names></name><name><surname>Morison</surname><given-names>JK</given-names></name><name><surname>Gibson</surname><given-names>BES</given-names></name><name><surname>Keeshan</surname><given-names>K</given-names></name></person-group><article-title>Insights into cell ontogeny, age, and acute myeloid leukemia</article-title><source>Experimental Hematology</source><year>2015</year><volume>43</volume><fpage>745</fpage><lpage>755</lpage><?supplied-pmid 26051919?><pub-id pub-id-type="pmid">26051919</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micel</surname><given-names>LN</given-names></name><name><surname>Tentler</surname><given-names>JJ</given-names></name><name><surname>Smith</surname><given-names>PG</given-names></name><name><surname>Eckhardt</surname><given-names>GS</given-names></name></person-group><article-title>Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies</article-title><source>Journal of Clinical Oncology</source><year>2013</year><volume>31</volume><fpage>1231</fpage><lpage>1238</lpage><?supplied-pmid 23358974?><pub-id pub-id-type="pmid">23358974</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasian</surname><given-names>SK</given-names></name><name><surname>Hunger</surname><given-names>SP</given-names></name></person-group><article-title>Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics</article-title><source>British Journal of Haematology</source><year>2017</year><volume>176</volume><fpage>867</fpage><lpage>882</lpage><?supplied-pmid 27984637?><pub-id pub-id-type="pmid">27984637</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prada-Arismendy</surname><given-names>J</given-names></name><name><surname>Arroyave</surname><given-names>JC</given-names></name><name><surname>R&#x000f6;thlisberger</surname><given-names>S</given-names></name></person-group><article-title>Molecular biomarkers in acute myeloid leukemia</article-title><source>Blood Reviews</source><year>2017</year><volume>31</volume><fpage>63</fpage><lpage>76</lpage><?supplied-pmid 27639498?><pub-id pub-id-type="pmid">27639498</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name></person-group><article-title>The proteasome: a suitable antineoplastic target</article-title><source>Nature Reviews. Cancer</source><year>2004</year><volume>4</volume><fpage>349</fpage><lpage>360</lpage><?supplied-pmid 15122206?><pub-id pub-id-type="pmid">15122206</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma</article-title><source>Journal of Clinical Oncology</source><year>2012</year><volume>30</volume><fpage>445</fpage><lpage>452</lpage><?supplied-pmid 22215754?><pub-id pub-id-type="pmid">22215754</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>P</given-names></name><name><surname>Ramakrishnan</surname><given-names>V</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name></person-group><article-title>Bortezomib combination therapy in multiple myeloma</article-title><source>Seminars in Hematology</source><year>2012</year><volume>49</volume><fpage>228</fpage><lpage>242</lpage><?supplied-pmid 22726546?><pub-id pub-id-type="pmid">22726546</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>JJ</given-names></name></person-group><article-title>Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy</article-title><source>Clinical Cancer Research</source><year>2010</year><volume>16</volume><fpage>4094</fpage><lpage>4104</lpage><?supplied-pmid 20682705?><pub-id pub-id-type="pmid">20682705</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parlati</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Aujay</surname><given-names>M</given-names></name><etal/></person-group><article-title>Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>3439</fpage><lpage>3447</lpage><?supplied-pmid 19671918?><pub-id pub-id-type="pmid">19671918</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Kaspers</surname><given-names>GJL</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy</article-title><source>Journal of Hematology &#x00026; Oncology</source><year>2016</year><volume>9</volume><fpage>82</fpage><pub-id pub-id-type="pmid">27599459</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbrugge</surname><given-names>SE</given-names></name><name><surname>Scheper</surname><given-names>RJ</given-names></name><name><surname>Lems</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Proteasome inhibitors as experimental therapeutics of autoimmune diseases</article-title><source>Arthritis Research &#x00026; Therapy</source><year>2015</year><volume>17</volume><fpage>17</fpage><pub-id pub-id-type="pmid">25889583</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Kaspers</surname><given-names>GJL</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Interferon-&#x003b3;-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines</article-title><source>Journal of Hematology &#x00026; Oncology</source><year>2014</year><volume>7</volume><fpage>7</fpage><pub-id pub-id-type="pmid">24418325</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basler</surname><given-names>M</given-names></name><name><surname>Kirk</surname><given-names>CJ</given-names></name><name><surname>Groettrup</surname><given-names>M</given-names></name></person-group><article-title>The immunoproteasome in antigen processing and other immunological functions</article-title><source>Current Opinion in Immunology</source><year>2012</year><volume>25</volume><fpage>74</fpage><lpage>80</lpage><?supplied-pmid 23219269?><pub-id pub-id-type="pmid">23219269</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>U</given-names></name><name><surname>Bialy</surname><given-names>LP</given-names></name><name><surname>Ebstein</surname><given-names>F</given-names></name><etal/></person-group><article-title>Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress</article-title><source>Cell</source><year>2010</year><volume>142</volume><fpage>613</fpage><lpage>624</lpage><?supplied-pmid 20723761?><pub-id pub-id-type="pmid">20723761</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>Z</given-names></name><name><surname>Ao</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name></person-group><article-title>Inhibitors of the immunoproteasome: current status and future directions</article-title><source>Current Pharmaceutical Design</source><year>2013</year><volume>19</volume><fpage>4140</fpage><lpage>4151</lpage><?supplied-pmid 23181576?><pub-id pub-id-type="pmid">23181576</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>YK</given-names></name><name><surname>Bargagna-Mohan</surname><given-names>P</given-names></name><name><surname>Wehenkel</surname><given-names>M</given-names></name><etal/></person-group><article-title>LMP2-specific inhibitors: chemical genetic tools for proteasome biology</article-title><source>Chemistry &#x00026; Biology</source><year>2007</year><volume>14</volume><fpage>419</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">17462577</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myung</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>KB</given-names></name><name><surname>Lindsten</surname><given-names>K</given-names></name><etal/></person-group><article-title>Lack of proteasome active site allostery as revealed by subunit-specific inhibitors</article-title><source>Molecular Cell</source><year>2001</year><volume>7</volume><fpage>411</fpage><lpage>420</lpage><?supplied-pmid 11239469?><pub-id pub-id-type="pmid">11239469</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Hunsucker</surname><given-names>SA</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>4667</fpage><lpage>4676</lpage><?supplied-pmid 19050304?><pub-id pub-id-type="pmid">19050304</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin</surname><given-names>G</given-names></name><name><surname>Huber</surname><given-names>EM</given-names></name><name><surname>Xin</surname><given-names>B-T</given-names></name><etal/></person-group><article-title>Structure-based design of &#x003b2;1i or &#x003b2;5i specific inhibitors of human immunoproteasomes</article-title><source>Journal of Medicinal Chemistry</source><year>2014</year><volume>57</volume><fpage>6197</fpage><lpage>6209</lpage><?supplied-pmid 25006746?><pub-id pub-id-type="pmid">25006746</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Orlowski</surname><given-names>RZ</given-names></name></person-group><article-title>The immunoproteasome as a target in hematologic malignancies</article-title><source>Seminars in Hematology</source><year>2012</year><volume>49</volume><fpage>258</fpage><lpage>262</lpage><?supplied-pmid 22726549?><pub-id pub-id-type="pmid">22726549</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>AF</given-names></name><name><surname>van der Linden</surname><given-names>WA</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name></person-group><article-title>Proteasome inhibitors: an expanding army attacking a unique target</article-title><source>Chemistry &#x00026; Biology</source><year>2012</year><volume>19</volume><fpage>99</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">22284358</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>EM</given-names></name><name><surname>Basler</surname><given-names>M</given-names></name><name><surname>Schwab</surname><given-names>R</given-names></name><etal/></person-group><article-title>Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>727</fpage><lpage>738</lpage><?supplied-pmid 22341445?><pub-id pub-id-type="pmid">22341445</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muchamuel</surname><given-names>T</given-names></name><name><surname>Basler</surname><given-names>M</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><etal/></person-group><article-title>A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis</article-title><source>Nature Medicine</source><year>2009</year><volume>15</volume><fpage>781</fpage><lpage>787</lpage><?supplied-pmid 19525961?><pub-id pub-id-type="pmid">19525961</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H-J</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><name><surname>Bennett</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</article-title><source>Journal of Medicinal Chemistry</source><year>2009</year><volume>52</volume><fpage>3028</fpage><lpage>3038</lpage><?supplied-pmid 19348473?><pub-id pub-id-type="pmid">19348473</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>van Meerloo</surname><given-names>J</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924</article-title><source>Biochemical Pharmacology</source><year>2014</year><volume>89</volume><fpage>43</fpage><lpage>51</lpage><?supplied-pmid 24552657?><pub-id pub-id-type="pmid">24552657</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AV</given-names></name><name><surname>Bandi</surname><given-names>M</given-names></name><name><surname>Aujay</surname><given-names>MA</given-names></name><etal/></person-group><article-title>PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo</article-title><source>British Journal of Haematology</source><year>2011</year><volume>152</volume><fpage>155</fpage><lpage>163</lpage><?supplied-pmid 21114484?><pub-id pub-id-type="pmid">21114484</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Riethoff</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)</article-title><source>Molecular Pharmacology</source><year>2014</year><volume>86</volume><fpage>12</fpage><lpage>19</lpage><?supplied-pmid 24737138?><pub-id pub-id-type="pmid">24737138</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Palombella</surname><given-names>VJ</given-names></name><name><surname>Elliott</surname><given-names>PJ</given-names></name></person-group><article-title>Proteasome inhibition: a new strategy in cancer treatment</article-title><source>Investigational New Drugs</source><year>2000</year><volume>18</volume><fpage>109</fpage><lpage>121</lpage><?supplied-pmid 10857991?><pub-id pub-id-type="pmid">10857991</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almond</surname><given-names>JB</given-names></name><name><surname>Cohen</surname><given-names>GM</given-names></name></person-group><article-title>The proteasome: a novel target for cancer chemotherapy</article-title><source>Leukemia</source><year>2002</year><volume>16</volume><fpage>433</fpage><lpage>443</lpage><?supplied-pmid 11960320?><pub-id pub-id-type="pmid">11960320</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Behnke</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids</article-title><source>Bioorganic &#x00026; Medicinal Chemistry Letters</source><year>1998</year><volume>8</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">9871680</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Proteasome inhibitors: valuable new tools for cell biologists</article-title><source>Trends in Cell Biology</source><year>1998</year><volume>8</volume><fpage>397</fpage><lpage>403</lpage><?supplied-pmid 9789328?><pub-id pub-id-type="pmid">9789328</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>AF</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Proteasome inhibitors: from research tools to drug candidates</article-title><source>Chemistry &#x00026; Biology</source><year>2001</year><volume>8</volume><fpage>739</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">11514224</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>J</given-names></name></person-group><article-title>The proteasome: structure, function, and role in the cell</article-title><source>Cancer Treatment Reviews</source><year>2000</year><volume>29</volume><issue>Suppl 1</issue><fpage>3</fpage><lpage>9</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>A novel proteasome inhibitor NPI-0052 as an anticancer therapy</article-title><source>British Journal of Cancer</source><year>2006</year><volume>95</volume><fpage>961</fpage><lpage>965</lpage><?supplied-pmid 17047643?><pub-id pub-id-type="pmid">17047643</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>AV</given-names></name><name><surname>Aujay</surname><given-names>M</given-names></name><etal/></person-group><article-title>A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>4906</fpage><lpage>4915</lpage><?supplied-pmid 20805366?><pub-id pub-id-type="pmid">20805366</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><etal/></person-group><article-title>In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells</article-title><source>Clinical Cancer Research</source><year>2011</year><volume>17</volume><fpage>5311</fpage><lpage>5321</lpage><?supplied-pmid 21724551?><pub-id pub-id-type="pmid">21724551</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>3281</fpage><lpage>3290</lpage><?supplied-pmid 17591945?><pub-id pub-id-type="pmid">17591945</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piva</surname><given-names>R</given-names></name><name><surname>Ruggeri</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><etal/></person-group><article-title>CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib</article-title><source>Blood</source><year>2008</year><volume>111</volume><fpage>2765</fpage><lpage>2775</lpage><?supplied-pmid 18057228?><pub-id pub-id-type="pmid">18057228</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>LR</given-names></name><name><surname>Fleming</surname><given-names>PE</given-names></name></person-group><article-title>Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</article-title><source>Drug Discovery Today</source><year>2010</year><volume>15</volume><fpage>243</fpage><lpage>249</lpage><?supplied-pmid 20116451?><pub-id pub-id-type="pmid">20116451</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Molecular basis of resistance to proteasome inhibitors in hematological malignancies</article-title><source>Drug Resistance Updates</source><year>2015</year><volume>18</volume><fpage>18</fpage><lpage>35</lpage><?supplied-pmid 25670156?><pub-id pub-id-type="pmid">25670156</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruschak</surname><given-names>AM</given-names></name><name><surname>Slassi</surname><given-names>M</given-names></name><name><surname>Kay</surname><given-names>LE</given-names></name><name><surname>Schimmer</surname><given-names>AD</given-names></name></person-group><article-title>Novel proteasome inhibitors to overcome bortezomib resistance</article-title><source>Journal of the National Cancer Institute</source><year>2011</year><volume>103</volume><fpage>1007</fpage><lpage>1017</lpage><?supplied-pmid 21606441?><pub-id pub-id-type="pmid">21606441</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>AJ</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name></person-group><article-title>Molecular mechanisms of acquired proteasome inhibitor resistance</article-title><source>Journal of Medicinal Chemistry</source><year>2012</year><volume>55</volume><fpage>10317</fpage><lpage>10327</lpage><?supplied-pmid 22978849?><pub-id pub-id-type="pmid">22978849</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirk</surname><given-names>CJ</given-names></name></person-group><article-title>Discovery and development of second-generation proteasome inhibitors</article-title><source>Seminars in Hematology</source><year>2012</year><volume>49</volume><fpage>207</fpage><lpage>214</lpage><?supplied-pmid 22726543?><pub-id pub-id-type="pmid">22726543</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Franke</surname><given-names>NE</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><etal/></person-group><article-title>Higher ratio immune vs. constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors</article-title><source>Haematologica</source><year>2013</year><volume>98</volume><fpage>1896</fpage><lpage>1904</lpage><?supplied-pmid 24056819?><pub-id pub-id-type="pmid">24056819</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drexler</surname><given-names>HC</given-names></name></person-group><article-title>Activation of the cell death program by inhibition of proteasome function</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>1997</year><volume>94</volume><fpage>855</fpage><lpage>860</lpage><?supplied-pmid 9023346?><pub-id pub-id-type="pmid">9023346</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soligo</surname><given-names>D</given-names></name><name><surname>Servida</surname><given-names>F</given-names></name><name><surname>Delia</surname><given-names>D</given-names></name><etal/></person-group><article-title>The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI</article-title><source>British Journal of Haematology</source><year>2001</year><volume>113</volume><fpage>126</fpage><lpage>135</lpage><?supplied-pmid 11328292?><pub-id pub-id-type="pmid">11328292</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrana</surname><given-names>JA</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name></person-group><article-title>Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade</article-title><source>Blood</source><year>2001</year><volume>97</volume><fpage>2105</fpage><lpage>2114</lpage><?supplied-pmid 11264178?><pub-id pub-id-type="pmid">11264178</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>J</given-names></name><name><surname>Niemer</surname><given-names>I</given-names></name><name><surname>Gilbreath</surname><given-names>J</given-names></name><etal/></person-group><article-title>Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>4220</fpage><lpage>4229</lpage><?supplied-pmid 9834227?><pub-id pub-id-type="pmid">9834227</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Rahmani</surname><given-names>M</given-names></name><name><surname>Grant</surname><given-names>S</given-names></name></person-group><article-title>Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7108</fpage><lpage>7122</lpage><?supplied-pmid 14562039?><pub-id pub-id-type="pmid">14562039</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahler</surname><given-names>JC</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name><name><surname>Niemer</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia</article-title><source>Clinical Cancer Research</source><year>2003</year><volume>9</volume><fpage>4570</fpage><lpage>4577</lpage><?supplied-pmid 14555532?><pub-id pub-id-type="pmid">14555532</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Rahmani</surname><given-names>M</given-names></name><name><surname>Pei</surname><given-names>XY</given-names></name><etal/></person-group><article-title>Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>509</fpage><lpage>518</lpage><?supplied-pmid 15039284?><pub-id pub-id-type="pmid">15039284</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duechler</surname><given-names>M</given-names></name><name><surname>Shehata</surname><given-names>M</given-names></name><name><surname>Schwarzmeier</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Induction of apoptosis by proteasome inhibitors in B-CLL cells is associated with downregulation of CD23 and inactivation of Notch2</article-title><source>Leukemia</source><year>2005</year><volume>19</volume><fpage>260</fpage><lpage>267</lpage><?supplied-pmid 15565166?><pub-id pub-id-type="pmid">15565166</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>TM</given-names></name><name><surname>Gannavarapu</surname><given-names>A</given-names></name><name><surname>Blaney</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Bortezomib interactions with chemotherapy agents in acute leukemia in vitro</article-title><source>Cancer Chemotherapy and Pharmacology</source><year>2006</year><volume>58</volume><fpage>13</fpage><lpage>23</lpage><?supplied-pmid 16292537?><pub-id pub-id-type="pmid">16292537</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanamandra</surname><given-names>N</given-names></name><name><surname>Colaco</surname><given-names>NM</given-names></name><name><surname>Parquet</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia</article-title><source>Clinical Cancer Research</source><year>2006</year><volume>12</volume><fpage>591</fpage><lpage>599</lpage><?supplied-pmid 16428505?><pub-id pub-id-type="pmid">16428505</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houghton</surname><given-names>PJ</given-names></name><name><surname>Morton</surname><given-names>CL</given-names></name><name><surname>Kolb</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program</article-title><source>Pediatric Blood &#x00026; Cancer</source><year>2008</year><volume>50</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">17420992</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Servida</surname><given-names>F</given-names></name><name><surname>Soligo</surname><given-names>D</given-names></name><name><surname>Delia</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I</article-title><source>Leukemia</source><year>2005</year><volume>19</volume><fpage>2324</fpage><lpage>2331</lpage><?supplied-pmid 16224484?><pub-id pub-id-type="pmid">16224484</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapnes</surname><given-names>C</given-names></name><name><surname>Doskeland</surname><given-names>AP</given-names></name><name><surname>Hatfield</surname><given-names>K</given-names></name><etal/></person-group><article-title>The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells</article-title><source>British Journal of Haematology</source><year>2007</year><volume>136</volume><fpage>814</fpage><lpage>828</lpage><?supplied-pmid 17341267?><pub-id pub-id-type="pmid">17341267</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Muller-Ide</surname><given-names>H</given-names></name><name><surname>Ruckrich</surname><given-names>T</given-names></name><etal/></person-group><article-title>Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations</article-title><source>Leukemia Research</source><year>2014</year><volume>38</volume><fpage>383</fpage><lpage>392</lpage><?supplied-pmid 24418752?><pub-id pub-id-type="pmid">24418752</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Westergard</surname><given-names>TD</given-names></name><name><surname>Cashen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>530</fpage><lpage>542</lpage><?supplied-pmid 24735925?><pub-id pub-id-type="pmid">24735925</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CP</given-names></name><name><surname>Rudra</surname><given-names>S</given-names></name><name><surname>Keating</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>4289</fpage><lpage>4299</lpage><?supplied-pmid 19182209?><pub-id pub-id-type="pmid">19182209</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CP</given-names></name><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Dujka</surname><given-names>ME</given-names></name><etal/></person-group><article-title>NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>267</fpage><lpage>277</lpage><?supplied-pmid 17356134?><pub-id pub-id-type="pmid">17356134</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>A</given-names></name><name><surname>Masood</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>KC</given-names></name><etal/></person-group><article-title>The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs</article-title><source>British Journal of Haematology</source><year>2014</year><volume>165</volume><fpage>78</fpage><lpage>88</lpage><?supplied-pmid 24467634?><pub-id pub-id-type="pmid">24467634</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>NE</given-names></name><name><surname>Vink</surname><given-names>J</given-names></name><name><surname>Cloos</surname><given-names>J</given-names></name><name><surname>Kaspers</surname><given-names>GJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Kaspers</surname><given-names>GJ</given-names></name><name><surname>Coiffier</surname><given-names>B</given-names></name><name><surname>Heinrich</surname><given-names>M</given-names></name><name><surname>Estey</surname><given-names>E</given-names></name></person-group><article-title>Proteasome and protease inhibitors</article-title><source>Innov. Leuk. Lymphoma Ther</source><year>2008</year><publisher-loc>New York</publisher-loc><publisher-name>Informa Healthcare USA, Inc.</publisher-name><fpage>469</fpage><lpage>489</lpage></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oerlemans</surname><given-names>R</given-names></name><name><surname>Franke</surname><given-names>NE</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>2489</fpage><lpage>2499</lpage><?supplied-pmid 18565852?><pub-id pub-id-type="pmid">18565852</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line</article-title><source>Experimental Hematology</source><year>2009</year><volume>37</volume><fpage>831</fpage><lpage>837</lpage><?supplied-pmid 19426847?><pub-id pub-id-type="pmid">19426847</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ri</surname><given-names>M</given-names></name><name><surname>Iida</surname><given-names>S</given-names></name><name><surname>Nakashima</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress</article-title><source>Leukemia</source><year>2010</year><volume>24</volume><fpage>1506</fpage><lpage>1512</lpage><?supplied-pmid 20555361?><pub-id pub-id-type="pmid">20555361</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>NE</given-names></name><name><surname>Niewerth</surname><given-names>D</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><fpage>757</fpage><lpage>768</lpage><?supplied-pmid 21941364?><pub-id pub-id-type="pmid">21941364</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConkey</surname><given-names>DJ</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name></person-group><article-title>Mechanisms of proteasome inhibitor action and resistance in cancer</article-title><source>Drug Resistance Updates</source><year>2008</year><volume>11</volume><fpage>164</fpage><lpage>179</lpage><?supplied-pmid 18818117?><pub-id pub-id-type="pmid">18818117</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>NE</given-names></name><name><surname>Kaspers</surname><given-names>GL</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors</article-title><source>Oncotarget</source><year>2014</year><volume>7</volume><fpage>74779</fpage><lpage>74796</lpage></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busse</surname><given-names>A</given-names></name><name><surname>Kraus</surname><given-names>M</given-names></name><name><surname>Na</surname><given-names>IK</given-names></name><etal/></person-group><article-title>Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits</article-title><source>Cancer</source><year>2008</year><volume>112</volume><fpage>659</fpage><lpage>670</lpage><?supplied-pmid 18181098?><pub-id pub-id-type="pmid">18181098</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>D</given-names></name><name><surname>Berges</surname><given-names>C</given-names></name><name><surname>Opelz</surname><given-names>G</given-names></name><etal/></person-group><article-title>Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells</article-title><source>Journal of Cellular Biochemistry</source><year>2008</year><volume>103</volume><fpage>270</fpage><lpage>283</lpage><?supplied-pmid 17516511?><pub-id pub-id-type="pmid">17516511</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frisan</surname><given-names>T</given-names></name><name><surname>Levitsky</surname><given-names>V</given-names></name><name><surname>Masucci</surname><given-names>MG</given-names></name></person-group><article-title>Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells</article-title><source>International Journal of Cancer</source><year>2000</year><volume>88</volume><fpage>881</fpage><lpage>888</lpage><?supplied-pmid 11093809?><pub-id pub-id-type="pmid">11093809</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line</article-title><source>Experimental Hematology</source><year>2008</year><volume>36</volume><fpage>1278</fpage><lpage>1284</lpage><?supplied-pmid 18562081?><pub-id pub-id-type="pmid">18562081</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbrugge</surname><given-names>SE</given-names></name><name><surname>Al</surname><given-names>M</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Overcoming bortezomib resistance in human B cells by anti-CD20 / rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors</article-title><source>Experimental Hematology &#x00026; Oncology</source><year>2013</year><volume>2</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23305345</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilt</surname><given-names>LHAM</given-names></name><name><surname>Jansen</surname><given-names>G</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><etal/></person-group><article-title>Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer</article-title><source>Biochemical Pharmacology</source><year>2012</year><volume>83</volume><fpage>207</fpage><lpage>217</lpage><?supplied-pmid 22027222?><pub-id pub-id-type="pmid">22027222</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>AJ</given-names></name><name><surname>McGlinchey</surname><given-names>RP</given-names></name><name><surname>Lechner</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>BS</given-names></name></person-group><article-title>Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A</article-title><source>ACS Chemical Biology</source><year>2011</year><volume>6</volume><fpage>1257</fpage><lpage>1264</lpage><?supplied-pmid 21882868?><pub-id pub-id-type="pmid">21882868</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Demo</surname><given-names>S</given-names></name><name><surname>Deu</surname><given-names>E</given-names></name><etal/></person-group><article-title>Molecular mechanisms of bortezomib resistant adenocarcinoma cells</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e27996</fpage><?supplied-pmid 22216088?><pub-id pub-id-type="pmid">22216088</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groll</surname><given-names>M</given-names></name><name><surname>Berkers</surname><given-names>CR</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Ovaa</surname><given-names>H</given-names></name></person-group><article-title>Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome</article-title><source>Structure</source><year>2006</year><volume>14</volume><fpage>451</fpage><lpage>456</lpage><?supplied-pmid 16531229?><pub-id pub-id-type="pmid">16531229</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>KB</given-names></name><name><surname>Tuvim</surname><given-names>MJ</given-names></name><name><surname>Dickey</surname><given-names>BF</given-names></name></person-group><article-title>Regulated mucin secretion from airway epithelial cells</article-title><source>Front Endocrinol (Lausanne)</source><year>2013</year><volume>4</volume><fpage>129</fpage><pub-id pub-id-type="pmid">24065956</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buschow</surname><given-names>SI</given-names></name><name><surname>Liefhebber</surname><given-names>JMP</given-names></name><name><surname>Wubbolts</surname><given-names>R</given-names></name><name><surname>Stoorvogel</surname><given-names>W</given-names></name></person-group><article-title>Exosomes contain ubiquitinated proteins</article-title><source>Blood Cells Mol Dis</source><year>2005</year><volume>35</volume><fpage>398</fpage><lpage>403</lpage><?supplied-pmid 16203162?><pub-id pub-id-type="pmid">16203162</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>E</given-names></name><name><surname>Kaufman</surname><given-names>JL</given-names></name><name><surname>Flowers</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>5285</fpage><lpage>5288</lpage><?supplied-pmid 20844234?><pub-id pub-id-type="pmid">20844234</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escalante</surname><given-names>AM</given-names></name><name><surname>McGrath</surname><given-names>RT</given-names></name><name><surname>Karolak</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo</article-title><source>Cancer Chemotherapy and Pharmacology</source><year>2013</year><volume>71</volume><fpage>1567</fpage><lpage>1576</lpage><?supplied-pmid 23572175?><pub-id pub-id-type="pmid">23572175</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamouda</surname><given-names>M-A</given-names></name><name><surname>Belhacene</surname><given-names>N</given-names></name><name><surname>Puissant</surname><given-names>A</given-names></name><etal/></person-group><article-title>The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>6252</fpage><lpage>6266</lpage><?supplied-pmid 25051369?><pub-id pub-id-type="pmid">25051369</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>B</given-names></name><name><surname>Benavides</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of autophagy on multiple myeloma cell viability</article-title><source>Molecular Cancer Therapeutics</source><year>2009</year><volume>8</volume><fpage>1974</fpage><lpage>1984</lpage><?supplied-pmid 19509276?><pub-id pub-id-type="pmid">19509276</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milani</surname><given-names>M</given-names></name><name><surname>Rzymski</surname><given-names>T</given-names></name><name><surname>Mellor</surname><given-names>HR</given-names></name><etal/></person-group><article-title>The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib</article-title><source>Cancer Research</source><year>2009</year><volume>69</volume><fpage>4415</fpage><lpage>4423</lpage><?supplied-pmid 19417138?><pub-id pub-id-type="pmid">19417138</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis</article-title><source>Blood</source><year>2014</year><volume>124</volume><fpage>2687</fpage><lpage>2697</lpage><?supplied-pmid 25208888?><pub-id pub-id-type="pmid">25208888</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milan</surname><given-names>E</given-names></name><name><surname>Perini</surname><given-names>T</given-names></name><name><surname>Resnati</surname><given-names>M</given-names></name><etal/></person-group><article-title>A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>1161</fpage><lpage>1178</lpage><?supplied-pmid 26043024?><pub-id pub-id-type="pmid">26043024</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarauta</surname><given-names>V</given-names></name><name><surname>Jaime</surname><given-names>P</given-names></name><name><surname>Gonzalo</surname><given-names>O</given-names></name><etal/></person-group><article-title>Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo</article-title><source>Cancer Letters</source><year>2016</year><volume>382</volume><fpage>1</fpage><lpage>10</lpage><?supplied-pmid 27565383?><pub-id pub-id-type="pmid">27565383</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baranowska</surname><given-names>K</given-names></name><name><surname>Misund</surname><given-names>K</given-names></name><name><surname>Starheim</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>70845</fpage><lpage>70856</lpage><?supplied-pmid 27683126?><pub-id pub-id-type="pmid">27683126</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Bradner</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma</article-title><source>Proceedings of the National Academy of Sciences</source><year>2005</year><volume>102</volume><fpage>8567</fpage><lpage>8572</lpage></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawrocki</surname><given-names>ST</given-names></name><name><surname>Carew</surname><given-names>JS</given-names></name><name><surname>Pino</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells</article-title><source>Cancer Research</source><year>2006</year><volume>66</volume><fpage>3773</fpage><lpage>3781</lpage><?supplied-pmid 16585204?><pub-id pub-id-type="pmid">16585204</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sriram</surname><given-names>SM</given-names></name><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name></person-group><article-title>Partners in crime: ubiquitin-mediated degradation and autophagy</article-title><source>Science Signaling</source><year>2011</year><volume>4</volume><fpage>jc4</fpage><?supplied-pmid 21693762?><pub-id pub-id-type="pmid">21693762</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Rhyasen</surname><given-names>G</given-names></name><name><surname>Bolanos</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>858</fpage><lpage>867</lpage><?supplied-pmid 22685174?><pub-id pub-id-type="pmid">22685174</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Ching</surname><given-names>YQ</given-names></name><name><surname>Chng</surname><given-names>W-J</given-names></name></person-group><article-title>Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>5490</fpage><lpage>5500</lpage><?supplied-pmid 25823927?><pub-id pub-id-type="pmid">25823927</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosman</surname><given-names>MCJ</given-names></name><name><surname>Schuringa</surname><given-names>JJ</given-names></name><name><surname>Quax</surname><given-names>WJ</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name></person-group><article-title>Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-&#x003ba;B and the accumulation of MCL-1</article-title><source>Experimental Hematology</source><year>2013</year><volume>41</volume><fpage>530</fpage><lpage>538.e1</lpage><?supplied-pmid 23416210?><pub-id pub-id-type="pmid">23416210</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markovina</surname><given-names>S</given-names></name><name><surname>Callander</surname><given-names>NS</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-&#x003ba;B activity in myeloma cells</article-title><source>Molecular Cancer</source><year>2010</year><volume>9</volume><fpage>176</fpage><?supplied-pmid 20604947?><pub-id pub-id-type="pmid">20604947</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markovina</surname><given-names>S</given-names></name><name><surname>Callander</surname><given-names>NS</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Bortezomib-resistant nuclear factor-&#x003ba;B activity in multiple myeloma cells</article-title><source>Molecular Cancer Research</source><year>2008</year><volume>6</volume><fpage>1356</fpage><lpage>1364</lpage><?supplied-pmid 18708367?><pub-id pub-id-type="pmid">18708367</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Chauhan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bortezomib induces canonical nuclear factor-&#x003ba;B activation in multiple myeloma cells</article-title><source>Blood</source><year>2009</year><volume>114</volume><fpage>1046</fpage><lpage>1052</lpage><?supplied-pmid 19436050?><pub-id pub-id-type="pmid">19436050</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HJ</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Fayad</surname><given-names>L</given-names></name><etal/></person-group><article-title>Bortezomib-resistant nuclear factor &#x003ba;B expression in stem-like cells in mantle cell lymphoma</article-title><source>Experimental Hematology</source><year>2012</year><volume>40</volume><fpage>107</fpage><lpage>118.e2</lpage><?supplied-pmid 22024108?><pub-id pub-id-type="pmid">22024108</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>DT</given-names></name><name><surname>Young</surname><given-names>KH</given-names></name><name><surname>Kahl</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma</article-title><source>Molecular Cancer</source><year>2008</year><volume>7</volume><fpage>40</fpage><?supplied-pmid 18489772?><pub-id pub-id-type="pmid">18489772</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>J-E</given-names></name><etal/></person-group><article-title>The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells</article-title><source>Leukemia Research</source><year>2012</year><volume>36</volume><fpage>912</fpage><lpage>920</lpage><?supplied-pmid 22560334?><pub-id pub-id-type="pmid">22560334</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C-Y</given-names></name><name><surname>Shiau</surname><given-names>C-W</given-names></name><name><surname>Kuo</surname><given-names>H-Y</given-names></name><etal/></person-group><article-title>Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells</article-title><source>Haematologica</source><year>2013</year><volume>98</volume><fpage>729</fpage><lpage>738</lpage><?supplied-pmid 22983581?><pub-id pub-id-type="pmid">22983581</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Que</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chuang</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name></person-group><article-title>Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity</article-title><source>APMIS</source><year>2012</year><volume>120</volume><fpage>195</fpage><lpage>203</lpage><?supplied-pmid 22339676?><pub-id pub-id-type="pmid">22339676</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Berkova</surname><given-names>Z</given-names></name><name><surname>Jones</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>3260</fpage><lpage>3270</lpage><?supplied-pmid 22932796?><pub-id pub-id-type="pmid">22932796</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiso</surname><given-names>P</given-names></name><name><surname>Ocio</surname><given-names>EM</given-names></name><name><surname>Garayoa</surname><given-names>M</given-names></name><etal/></person-group><article-title>The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells</article-title><source>British Journal of Haematology</source><year>2008</year><volume>141</volume><fpage>470</fpage><lpage>482</lpage><?supplied-pmid 18341634?><pub-id pub-id-type="pmid">18341634</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K-D</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Burtrum</surname><given-names>D</given-names></name><etal/></person-group><article-title>Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis</article-title><source>Cancer Immunology, Immunotherapy</source><year>2006</year><volume>56</volume><fpage>343</fpage><lpage>357</lpage><?supplied-pmid 16832681?><pub-id pub-id-type="pmid">16832681</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung-Hagesteijn</surname><given-names>C</given-names></name><name><surname>Erdmann</surname><given-names>N</given-names></name><name><surname>Cheung</surname><given-names>G</given-names></name><etal/></person-group><article-title>Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>289</fpage><lpage>304</lpage><?supplied-pmid 24029229?><pub-id pub-id-type="pmid">24029229</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambella</surname><given-names>M</given-names></name><name><surname>Rocci</surname><given-names>A</given-names></name><name><surname>Passera</surname><given-names>R</given-names></name><etal/></person-group><article-title>High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib</article-title><source>Haematologica</source><year>2014</year><volume>99</volume><fpage>e14</fpage><lpage>e16</lpage><?supplied-pmid 24497562?><pub-id pub-id-type="pmid">24497562</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minderman</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>O&#x02019;Loughlin</surname><given-names>KL</given-names></name><name><surname>Baer</surname><given-names>MR</given-names></name></person-group><article-title>Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status</article-title><source>Cancer Chemotherapy and Pharmacology</source><year>2007</year><volume>60</volume><fpage>245</fpage><lpage>255</lpage><?supplied-pmid 17096161?><pub-id pub-id-type="pmid">17096161</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verbrugge</surname><given-names>SE</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><name><surname>Dijkmans</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><year>2012</year><volume>341</volume><fpage>174</fpage><lpage>182</lpage><?supplied-pmid 22235146?><pub-id pub-id-type="pmid">22235146</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ao</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><etal/></person-group><article-title>Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib</article-title><source>Molecular Pharmaceutics</source><year>2012</year><volume>9</volume><fpage>2197</fpage><lpage>2205</lpage><?supplied-pmid 22734651?><pub-id pub-id-type="pmid">22734651</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connor</surname><given-names>R</given-names></name><name><surname>Ooi</surname><given-names>MG</given-names></name><name><surname>Meiller</surname><given-names>J</given-names></name><etal/></person-group><article-title>The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias</article-title><source>Cancer Chemotherapy and Pharmacology</source><year>2013</year><volume>71</volume><fpage>1357</fpage><lpage>1368</lpage><?supplied-pmid 23589314?><pub-id pub-id-type="pmid">23589314</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaughnessy</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Qu</surname><given-names>P</given-names></name><name><surname>Usmani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3</article-title><source>Blood</source><year>2011</year><volume>118</volume><fpage>3512</fpage><lpage>3524</lpage><?supplied-pmid 21628408?><pub-id pub-id-type="pmid">21628408</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuqing</surname><given-names>L</given-names></name><name><surname>Jianmin</surname><given-names>Y</given-names></name><name><surname>Chongmei</surname><given-names>H</given-names></name><etal/></person-group><article-title>Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen</article-title><source>Experimental Hematology</source><year>2011</year><volume>39</volume><fpage>1117</fpage><lpage>1118</lpage><?supplied-pmid 21920470?><pub-id pub-id-type="pmid">21920470</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weniger</surname><given-names>MA</given-names></name><name><surname>Rizzatti</surname><given-names>EG</given-names></name><name><surname>Perez-Galan</surname><given-names>P</given-names></name><etal/></person-group><article-title>Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma</article-title><source>Clinical Cancer Research</source><year>2011</year><volume>17</volume><fpage>5101</fpage><lpage>5112</lpage><?supplied-pmid 21712452?><pub-id pub-id-type="pmid">21712452</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matondo</surname><given-names>M</given-names></name><name><surname>Bousquet-Dubouch</surname><given-names>MP</given-names></name><name><surname>Gallay</surname><given-names>N</given-names></name><etal/></person-group><article-title>Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status</article-title><source>Leukemia Research</source><year>2010</year><volume>34</volume><fpage>498</fpage><lpage>506</lpage><?supplied-pmid 19811823?><pub-id pub-id-type="pmid">19811823</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Fridley</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics</article-title><source>Clinical Cancer Research</source><year>2008</year><volume>14</volume><fpage>3503</fpage><lpage>3513</lpage><?supplied-pmid 18519783?><pub-id pub-id-type="pmid">18519783</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichter</surname><given-names>DI</given-names></name><name><surname>Danaee</surname><given-names>H</given-names></name><name><surname>Pickard</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Sequence analysis of &#x003b2;-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>4513</fpage><lpage>4516</lpage><?supplied-pmid 23018640?><pub-id pub-id-type="pmid">23018640</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrio</surname><given-names>S</given-names></name><name><surname>St&#x000fc;hmer</surname><given-names>T</given-names></name><name><surname>Teufel</surname><given-names>E</given-names></name><etal/></person-group><article-title>Parallel evolution of multiple PSMB5 mutations in a myeloma patient treated with bortezomib</article-title><source>Blood</source><year>2016</year><volume>128</volume><fpage>3282</fpage></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachas</surname><given-names>C</given-names></name><name><surname>Schuurhuis</surname><given-names>GJ</given-names></name><name><surname>Reinhardt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse</article-title><source>British Journal of Haematology</source><year>2014</year><volume>166</volume><fpage>902</fpage><lpage>910</lpage><?supplied-pmid 24962064?><pub-id pub-id-type="pmid">24962064</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Micallef</surname><given-names>J</given-names></name><name><surname>Dharsee</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma</article-title><source>Journal of Hematology &#x00026; Oncology</source><year>2010</year><volume>3</volume><fpage>13</fpage><pub-id pub-id-type="pmid">20374647</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Saha</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Targeting phospho-MARCKS overcomes drug resistance and induces antitumor activity in preclinical models of multiple myeloma</article-title><source>Leukemia</source><year>2015</year><volume>29</volume><fpage>715</fpage><lpage>726</lpage><?supplied-pmid 25179733?><pub-id pub-id-type="pmid">25179733</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>K</given-names></name><name><surname>Hayden</surname><given-names>PJ</given-names></name><name><surname>Will</surname><given-names>A</given-names></name><etal/></person-group><person-group person-group-type="editor"><name><surname>Scott</surname><given-names>K</given-names></name><etal/></person-group><article-title>Bortezomib for the treatment of multiple myeloma</article-title><source>Cochrane Database Syst. Rev</source><year>2016</year><publisher-loc>Chichester</publisher-loc><publisher-name>John Wiley &#x00026; Sons, Ltd</publisher-name><fpage>CD010816</fpage></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Stinchcombe</surname><given-names>TE</given-names></name><name><surname>Mitchell</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies</article-title><source>Journal of Clinical Oncology</source><year>2002</year><volume>20</volume><fpage>4420</fpage><lpage>4427</lpage><?supplied-pmid 12431963?><pub-id pub-id-type="pmid">12431963</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortes</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Koller</surname><given-names>C</given-names></name><etal/></person-group><article-title>Phase I study of bortezomib in refractory or relapsed acute leukemias</article-title><source>Clinical Cancer Research</source><year>2004</year><volume>10</volume><fpage>3371</fpage><lpage>3376</lpage><?supplied-pmid 15161691?><pub-id pub-id-type="pmid">15161691</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orlowski</surname><given-names>RZ</given-names></name><name><surname>Voorhees</surname><given-names>PM</given-names></name><name><surname>Garcia</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>3058</fpage><lpage>3065</lpage><?supplied-pmid 15626743?><pub-id pub-id-type="pmid">15626743</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>TM</given-names></name><name><surname>Pati</surname><given-names>D</given-names></name><name><surname>Plon</surname><given-names>SE</given-names></name><etal/></person-group><article-title>A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children&#x02019;s Oncology Group study</article-title><source>Clinical Cancer Research</source><year>2007</year><volume>13</volume><fpage>1516</fpage><lpage>1522</lpage><?supplied-pmid 17332297?><pub-id pub-id-type="pmid">17332297</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attar</surname><given-names>EC</given-names></name><name><surname>De Angelo</surname><given-names>DJ</given-names></name><name><surname>Supko</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia</article-title><source>Clinical Cancer Research</source><year>2008</year><volume>14</volume><fpage>1446</fpage><lpage>1454</lpage><?supplied-pmid 18316568?><pub-id pub-id-type="pmid">18316568</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messinger</surname><given-names>Y</given-names></name><name><surname>Gaynon</surname><given-names>P</given-names></name><name><surname>Raetz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium</article-title><source>Pediatric Blood &#x00026; Cancer</source><year>2010</year><volume>55</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">20582937</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Messinger</surname><given-names>YH</given-names></name><name><surname>Gaynon</surname><given-names>PS</given-names></name><name><surname>Sposto</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia &#x00026; Lymphoma (TACL) Study</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>285</fpage><lpage>290</lpage><?supplied-pmid 22653976?><pub-id pub-id-type="pmid">22653976</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lancet</surname><given-names>JE</given-names></name><name><surname>Duong</surname><given-names>VH</given-names></name><name><surname>Winton</surname><given-names>EF</given-names></name><etal/></person-group><article-title>A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias</article-title><source>Clinical Cancer Research</source><year>2011</year><volume>17</volume><fpage>1140</fpage><lpage>1146</lpage><?supplied-pmid 21233404?><pub-id pub-id-type="pmid">21233404</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attar</surname><given-names>EC</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Amrein</surname><given-names>PC</given-names></name><etal/></person-group><article-title>Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502</article-title><source>Journal of Clinical Oncology</source><year>2013</year><volume>31</volume><fpage>923</fpage><lpage>929</lpage><?supplied-pmid 23129738?><pub-id pub-id-type="pmid">23129738</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>AR</given-names></name><name><surname>Klisovic</surname><given-names>R</given-names></name><name><surname>Johnston</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia</article-title><source>Leukemia &#x00026; Lymphoma</source><year>2013</year><volume>54</volume><fpage>1996</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">23256542</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>W</given-names></name><name><surname>Schwind</surname><given-names>S</given-names></name><name><surname>Tarighat</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>6025</fpage><lpage>6031</lpage><?supplied-pmid 22566605?><pub-id pub-id-type="pmid">22566605</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attar</surname><given-names>EC</given-names></name><name><surname>Amrein</surname><given-names>PC</given-names></name><name><surname>Fraser</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)</article-title><source>Leukemia Research</source><year>2013</year><volume>37</volume><fpage>1016</fpage><lpage>1020</lpage><?supplied-pmid 23773898?><pub-id pub-id-type="pmid">23773898</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>DS</given-names></name><name><surname>Liesveld</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>GL</given-names></name><etal/></person-group><article-title>A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia</article-title><source>Leukemia Research</source><year>2013</year><volume>37</volume><fpage>1502</fpage><lpage>1508</lpage><?supplied-pmid 24075534?><pub-id pub-id-type="pmid">24075534</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>AR</given-names></name><name><surname>Klisovic</surname><given-names>RB</given-names></name><name><surname>Garzon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia</article-title><source>Leukemia &#x00026; Lymphoma</source><year>2014</year><volume>55</volume><fpage>1304</fpage><lpage>1308</lpage><pub-id pub-id-type="pmid">23952243</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>AR</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia</article-title><source>Leukemia &#x00026; Lymphoma</source><year>2016</year><volume>57</volume><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="pmid">26784138</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wartman</surname><given-names>LD</given-names></name><name><surname>Fiala</surname><given-names>MA</given-names></name><name><surname>Fletcher</surname><given-names>T</given-names></name><etal/></person-group><article-title>A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia</article-title><source>Leukemia &#x00026; Lymphoma</source><year>2016</year><volume>57</volume><fpage>728</fpage><lpage>730</lpage><pub-id pub-id-type="pmid">26674111</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awan</surname><given-names>FT</given-names></name><name><surname>Flynn</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma</article-title><source>Leukemia &#x00026; Lymphoma</source><year>2015</year><volume>56</volume><fpage>2834</fpage><lpage>2840</lpage><pub-id pub-id-type="pmid">25669927</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>TM</given-names></name><name><surname>Perentesis</surname><given-names>JP</given-names></name><name><surname>Gamis</surname><given-names>AS</given-names></name><etal/></person-group><article-title>A phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children&#x02019;s Oncology Group</article-title><source>Pediatric Blood &#x00026; Cancer</source><year>2014</year><volume>61</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">24976003</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishitsuka</surname><given-names>K</given-names></name><name><surname>Utsunomiya</surname><given-names>A</given-names></name><name><surname>Katsuya</surname><given-names>H</given-names></name><etal/></person-group><article-title>A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma</article-title><source>Cancer Science</source><year>2015</year><volume>106</volume><fpage>1219</fpage><lpage>1223</lpage><?supplied-pmid 26179770?><pub-id pub-id-type="pmid">26179770</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Royer</surname><given-names>B</given-names></name><name><surname>Minvielle</surname><given-names>S</given-names></name><name><surname>Diouf</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My&#x000e9;lome</article-title><source>Journal of Clinical Oncology</source><year>2016</year><volume>34</volume><fpage>2125</fpage><lpage>2132</lpage><?supplied-pmid 27114594?><pub-id pub-id-type="pmid">27114594</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>KPC</given-names></name><name><surname>Bonuccelli</surname><given-names>G</given-names></name><name><surname>Duarte</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e61367</fpage><?supplied-pmid 23579193?><pub-id pub-id-type="pmid">23579193</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penna</surname><given-names>F</given-names></name><name><surname>Bonetto</surname><given-names>A</given-names></name><name><surname>Aversa</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><year>2016</year><volume>7</volume><fpage>345</fpage><lpage>354</lpage><?supplied-pmid 27239411?><pub-id pub-id-type="pmid">27239411</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>JG</given-names></name><name><surname>Kashyap</surname><given-names>T</given-names></name><name><surname>Dawson</surname><given-names>JL</given-names></name><etal/></person-group><article-title>XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I&#x003ba;B&#x003b1; and overcomes acquired proteasome inhibitor resistance in human multiple myeloma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>78896</fpage><lpage>78909</lpage><?supplied-pmid 27806331?><pub-id pub-id-type="pmid">27806331</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin</surname><given-names>G</given-names></name><name><surname>Xin</surname><given-names>BT</given-names></name><name><surname>Kraus</surname><given-names>M</given-names></name><etal/></person-group><article-title>A set of activity-based probes to visualize human (immuno)proteasome activities</article-title><source>Angewandte Chemie (International Ed. in English)</source><year>2016</year><volume>55</volume><fpage>4199</fpage><lpage>4203</lpage><pub-id pub-id-type="pmid">26511210</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Levitsky</surname><given-names>K</given-names></name><name><surname>Parlati</surname><given-names>F</given-names></name><etal/></person-group><article-title>Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay</article-title><source>British Journal of Haematology</source><year>2016</year><volume>173</volume><fpage>884</fpage><lpage>895</lpage><?supplied-pmid 27071340?><pub-id pub-id-type="pmid">27071340</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>KA</given-names></name><name><surname>Tsang</surname><given-names>A</given-names></name><name><surname>Sjoe</surname><given-names>M</given-names></name><name><surname>Niewerth</surname><given-names>D</given-names></name><etal/></person-group><article-title>Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis</article-title><source>Lupus Science &#x00026; Medicine</source><year>2015</year><volume>2</volume><fpage>e000121</fpage><pub-id pub-id-type="pmid">26719810</pub-id></element-citation></ref></ref-list></back></article>